Palisade Bio (PALI) S-4 23 Dec 20 2020 Q3 Registration of securities issued in business combination transactions Financial data

Document And Entity Information

Document And Entity Information	9 Months Ended
	Sep. 30, 2020
Document Information [Line Items]
Entity Registrant Name	Seneca Biopharma, Inc.
Entity Central Index Key	0001357459
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Document Type	S-4
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 5,114,917	$ 5,787,110
Trade and other receivables	21,064	294,057
Current portion of related party receivable, net of discount		63,938
Prepaid expenses	510,900	363,288
Total current assets	5,646,881	6,508,393
Property and equipment, net	41,036	90,311
Patents, net	668,936	763,543
Related party receivable, net of discount and current portion		298,238
ROU and other assets	227,036	23,965
Total assets	6,583,889	7,684,450
CURRENT LIABILITIES
Accounts payable and accrued expenses	824,406	832,564
Accrued bonuses	135,686
Short-term note and other current liabilities	264,665	218,602
Total current liabilities	1,224,757	1,051,166
Warrant liabilities, at fair value	84,596	583,734
Lease liability, net of current portion	148,543
Total liabilities	1,457,896	1,634,900
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY
Preferred stock, 7,000,000 shares authorized, $0.01 par value; 200,000 shares issued and outstanding at September 30, 2020 and December 31, 2019	2,000	10,000
Common stock, $0.01 par value; 300,000,000 shares authorized, 17,295,703 and 3,866,457 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	38,665	9,103
Additional paid-in capital	227,067,058	219,654,753
Accumulated other comprehensive loss	(6,186)	(413)
Accumulated deficit	(221,975,544)	(213,623,893)
Total stockholders' equity	5,125,993	6,049,550
Total liabilities and stockholders' equity	$ 6,583,889	$ 7,684,450

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000	7,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued (in shares)	200,000	200,000	1,000,000
Preferred stock, shares outstanding (in shares)	200,000	200,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000
Common stock, shares issued (in shares)	17,295,703	3,866,457	910,253
Common stock, shares outstanding (in shares)	17,295,703	3,866,457	910,253

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 15,394	$ 260,000
Operating expenses:
Research and development expenses	4,061,450	3,960,191
General and administrative expenses	4,585,638	4,559,265
Total operating expenses	8,647,088	8,519,456
Operating loss	(8,631,694)	(8,259,456)
Other income (expense):
Interest income	67,731	78,780
Interest expense	(8,920)	(7,698)
Gain on fair value of liability classified warrants	499,138	3,269,148
Write-off of related party receivable and other income (expense)	(277,906)	(5,391)
Total other income (expense)	280,043	3,334,839
Net loss	$ (8,351,651)	$ (4,924,617)
Net loss per share - basic and diluted (in dollars per share)	$ (3.80)	$ (7.54)
Weighted average common shares outstanding - basic and diluted (in shares)	2,197,434	653,221
Comprehensive loss:
Net loss	$ (8,351,651)	$ (4,924,617)
Foreign currency translation adjustment	(5,773)	(3,044)
Comprehensive loss	$ (8,357,424)	$ (4,927,661)

Consolidated Statements of Chan

Consolidated Statements of Changes In Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,000,000	758,001
Balance at Dec. 31, 2017	$ 10,000	$ 7,580	$ 217,194,194	$ 2,631	$ (208,699,276)	$ 8,515,129
Share-based payments			634,082			634,082
Issuance of common stock and warrants from capital raises, net (in shares)		150,000
Issuance of common stock and warrants from capital raises, net		$ 1,500	1,826,500			1,828,000
Issuance of restricted stock awards (in shares)		2,252
Issuance of restricted stock awards		$ 23	(23)
Foreign currency translation adjustments				(3,044)		(3,044)
Net loss					(4,924,617)	(4,924,617)
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Share-based payments			337,966			337,966
Foreign currency translation adjustments				(1,743)		(1,743)
Net loss					(3,113,992)	(3,113,992)
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Net loss						(6,314,047)
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	226,957,990	(7,670)	(219,937,940)	7,042,563
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Share-based payments			880,789			880,789
Issuance of common stock and warrants from capital raises, net (in shares)		416,315
Issuance of common stock and warrants from capital raises, net		$ 4,163	6,548,679			6,552,842
Issuance of restricted stock awards (in shares)		15,688
Issuance of restricted stock awards		$ 157	(157)
Foreign currency translation adjustments				(5,773)		(5,773)
Net loss					(8,351,651)	(8,351,651)
Share rounding adjustment related to 1:20 reverse stock split (in shares)		6,117
Share rounding adjustment related to 1:20 reverse stock split		$ 61	(61)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(800,000)	155,496
Issuance of common stock for conversion of Series A Preferred Stock	$ (8,000)	$ 1,555	6,445
Issuance of common stock for warrant exercises (in shares)		2,361,462
Issuance of common stock for warrant exercises		$ 23,615	(23,379)			236
Issuance of common stock for RSU exercises (in shares)		1,126
Issuance of common stock for RSU exercises		$ 11	(11)
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Share-based payments			128,778			128,778
Foreign currency translation adjustments				(1,013)		(1,013)
Net loss					(1,436,921)	(1,436,921)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(465,191)	90,419
Issuance of common stock for conversion of Series A Preferred Stock	$ (4,652)	$ 904	3,748
Issuance of common stock for RSU exercises (in shares)		1,126
Issuance of common stock for RSU exercises		$ 11	(11)
Balance (in shares) at Jun. 30, 2019	534,809	1,001,798
Balance at Jun. 30, 2019	$ 5,348	$ 10,018	220,125,234	(3,169)	(218,174,806)	1,962,625
Share-based payments			294,600			294,600
Issuance of common stock and warrants from capital raises, net (in shares)		416,315
Issuance of common stock and warrants from capital raises, net		$ 4,163	6,548,679			6,552,842
Issuance of restricted stock awards (in shares)		15,688
Issuance of restricted stock awards		$ 157	(157)
Foreign currency translation adjustments				(4,501)		(4,501)
Net loss					(1,763,134)	(1,763,134)
Share rounding adjustment related to 1:20 reverse stock split (in shares)		6,117
Share rounding adjustment related to 1:20 reverse stock split		$ 61	(61)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(334,809)	65,077
Issuance of common stock for conversion of Series A Preferred Stock	$ (3,348)	$ 651	2,697
Issuance of common stock for warrant exercises (in shares)		1,313,296
Issuance of common stock for warrant exercises		$ 13,133	(13,002)			131
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	226,957,990	(7,670)	(219,937,940)	7,042,563
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Share-based payments			75,892			75,892
Foreign currency translation adjustments				(962)		(962)
Net loss					(7,575,218)	(7,575,218)
Balance (in shares) at Mar. 31, 2020	200,000	9,428,011
Balance at Mar. 31, 2020	$ 2,000	$ 94,280	239,439,587	(7,148)	(229,550,762)	9,977,957
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Net loss						(11,847,981)
Balance (in shares) at Sep. 30, 2020	200,000	17,295,703
Balance at Sep. 30, 2020	$ 2,000	$ 172,957	247,775,027	(3,986)	(233,823,525)	14,122,473
Balance (in shares) at Mar. 31, 2020	200,000	9,428,011
Balance at Mar. 31, 2020	$ 2,000	$ 94,280	239,439,587	(7,148)	(229,550,762)	9,977,957
Share-based payments			241,247			241,247
Issuance of common stock and warrants from capital raises, net (in shares)		5,000,000
Issuance of common stock and warrants from capital raises, net		$ 50,000	4,384,354			4,434,354
Foreign currency translation adjustments				(18)		(18)
Net loss					(1,950,941)	(1,950,941)
Issuance of common stock for warrant exercises (in shares)		2,871,296
Issuance of common stock for warrant exercises		$ 28,713	3,502,981			3,531,694
Issuance of common stock for RSU exercises (in shares)		563
Issuance of common stock for RSU exercises		$ 6	(6)
Balance (in shares) at Jun. 30, 2020	200,000	17,295,703
Balance at Jun. 30, 2020	$ 2,000	$ 172,957	247,568,205	(7,166)	(231,501,703)	16,234,293
Share-based payments			206,822			206,822
Foreign currency translation adjustments				3,180		3,180
Net loss					(2,321,822)	(2,321,822)
Balance (in shares) at Sep. 30, 2020	200,000	17,295,703
Balance at Sep. 30, 2020	$ 2,000	$ 172,957	$ 247,775,027	$ (3,986)	$ (233,823,525)	$ 14,122,473

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (8,351,651)	$ (4,924,617)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	143,859	185,803
Share-based compensation expense	880,789	634,082
Gain on fair value of liability classified warrants	(499,138)	(3,269,148)
Allowance for bad debt	362,176
Loss on disposal of fixed assets and patent abandonment		18,342
Changes in operating assets and liabilities:
Trade and other receivables	272,993	18,745
Related party receivable		62,064
Prepaid expenses	(142,310)	32,303
ROU and other assets	39,643	(3,991)
Accounts payable and accrued expenses	(15,741)	(36,991)
Accrued bonuses	135,686	(418,625)
Other current liabilities	(47,414)	11,490
Lease and other long term liabilities	(34,572)	(1,876)
Net cash used in operating activities	(7,255,680)	(7,692,419)
Cash flows from investing activities:
Maturity of short-term investments		5,000,000
Purchase of property and equipment		(1,714)
Net cash provided by investing activities		4,998,286
Cash flows from financing activities:
Net proceeds from the sale of common stock and warrants	6,552,842	1,828,000
Proceeds from warrant exercises	236
Proceeds from short-term note payable	414,320	349,578
Payments of short-term note payable	(377,893)	(363,345)
Net cash provided by (used in) financing activities	6,589,505	1,814,233
Effects of exchange rates on cash	(6,018)	(7,930)
Net increase in cash and cash equivalents	(672,193)	(887,830)
Cash and cash equivalents, beginning of period	5,787,110	6,674,940
Cash and cash equivalents, end of period	5,114,917	5,787,110
Cash paid for interest	$ 8,920	$ 7,698

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 12,651,728			$ 5,114,917				$ 5,787,110
Trade and other receivables	8,779			21,064				294,057
Prepaid expenses	1,431,398			510,900				363,288
Assets held for sale	899,538
Total current assets	14,991,443			5,646,881				6,508,393
Property and equipment, net	15,040			41,036				90,311
Patents, net	152,625			668,936				763,543
ROU and other assets	10,439			227,036				23,965
Total assets	15,169,547			6,583,889				7,684,450
CURRENT LIABILITIES
Accounts payable and accrued expenses	577,558			824,406				832,564
Accrued bonuses	98,750			135,686
Short-term note and other current liabilities				264,665				218,602
Liabilities associated with assets held for sale	325,812
Total current liabilities	1,002,120			1,224,757				1,051,166
Warrant liabilities, at fair value	44,954			84,596				583,734
Lease liability, net of current portion				148,543
Total liabilities	1,047,074			1,457,896				1,634,900
Commitments and contingencies (Note 5)
STOCKHOLDERS' EQUITY
Preferred stock, 7,000,000 shares authorized, $0.01 par value; 200,000 shares issued and outstanding at September 30, 2020 and December 31, 2019	2,000			2,000				10,000
Common stock, $0.01 par value; 300,000,000 shares authorized, 17,295,703 and 3,866,457 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	172,957			38,665				9,103
Additional paid-in capital	247,775,027			227,067,058				219,654,753
Accumulated other comprehensive loss	(3,986)			(6,186)				(413)
Accumulated deficit	(233,823,525)			(221,975,544)				(213,623,893)
Total stockholders' equity	14,122,473	$ 16,234,293	$ 9,977,957	5,125,993	$ 7,042,563	$ 1,962,625	$ 3,271,781	6,049,550	$ 8,515,129
Total liabilities and stockholders' equity	$ 15,169,547			$ 6,583,889				$ 7,684,450

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Preferred stock, shares authorized (in shares)	7,000,000	7,000,000	7,000,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Preferred stock, shares issued (in shares)	200,000	200,000	1,000,000
Preferred stock, shares outstanding (in shares)	200,000	200,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	300,000,000	300,000,000	300,000,000
Common stock, shares issued (in shares)	17,295,703	3,866,457	910,253
Common stock, shares outstanding (in shares)	17,295,703	3,866,457	910,253

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues	$ 2,500	$ 2,500	$ 11,020	$ 12,894
Operating expenses:
Research and development expenses	466,014	825,486	1,608,935	3,294,402
General and administrative expenses	1,880,122	1,301,189	4,683,539	3,217,613
Total operating expenses	2,346,136	2,126,675	6,292,474	6,512,015
Operating loss	(2,343,636)	(2,124,175)	(6,281,454)	(6,499,121)
Other income (expense):
Interest income	7,731	15,234	27,935	55,086
Interest expense	(3,586)	(1,913)	(14,015)	(4,437)
Warrant inducement expense			(5,620,089)
Gain on fair value of liability classified warrants	17,669	320,785	39,642	416,796
Other income (expense)		26,935		(282,371)
Total other income (expense)	21,814	361,041	(5,566,527)	185,074
Net loss	$ (2,321,822)	$ (1,763,134)	$ (11,847,981)	$ (6,314,047)
Net loss per share - basic and diluted (in dollars per share)	$ (0.13)	$ (0.59)	$ (0.93)	$ (4.80)
Weighted average common shares outstanding - basic and diluted (in shares)	17,306,672	2,975,779	12,713,094	1,316,597
Comprehensive loss:
Net loss	$ (2,321,822)	$ (1,763,134)	$ (11,847,981)	$ (6,314,047)
Foreign currency translation adjustment	3,180	(4,501)	2,200	(7,257)
Comprehensive loss	$ (2,318,642)	$ (1,767,635)	$ (11,845,781)	$ (6,321,304)

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	1,000,000	758,001
Balance at Dec. 31, 2017	$ 10,000	$ 7,580	$ 217,194,194	$ 2,631	$ (208,699,276)	$ 8,515,129
Share-based payments			634,082			634,082
Foreign currency translation adjustments				(3,044)		(3,044)
Net loss					(4,924,617)	(4,924,617)
Issuance of common stock and warrants from capital raises, net (in shares)		150,000
Issuance of common stock and warrants from capital raises, net		$ 1,500	1,826,500			1,828,000
Issuance of restricted stock awards (in shares)		2,252
Issuance of restricted stock awards		$ 23	(23)
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Share-based payments			337,966			337,966
Foreign currency translation adjustments				(1,743)		(1,743)
Net loss					(3,113,992)	(3,113,992)
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Net loss						(6,314,047)
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	226,957,990	(7,670)	(219,937,940)	7,042,563
Balance (in shares) at Dec. 31, 2018	1,000,000	910,253
Balance at Dec. 31, 2018	$ 10,000	$ 9,103	219,654,753	(413)	(213,623,893)	6,049,550
Share-based payments			880,789			880,789
Foreign currency translation adjustments				(5,773)		(5,773)
Net loss					(8,351,651)	(8,351,651)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(800,000)	155,496
Issuance of common stock for conversion of Series A Preferred Stock	$ (8,000)	$ 1,555	6,445
Issuance of common stock for RSU exercises (in shares)		1,126
Issuance of common stock for RSU exercises		$ 11	(11)
Share rounding adjustment related to 1:20 reverse stock split (in shares)		6,117
Share rounding adjustment related to 1:20 reverse stock split		$ 61	(61)
Issuance of common stock and warrants from capital raises, net (in shares)		416,315
Issuance of common stock and warrants from capital raises, net		$ 4,163	6,548,679			6,552,842
Issuance of restricted stock awards (in shares)		15,688
Issuance of restricted stock awards		$ 157	(157)
Issuance of common stock for warrant exercises (in shares)		2,361,462
Issuance of common stock for warrant exercises		$ 23,615	(23,379)			236
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Balance (in shares) at Mar. 31, 2019	1,000,000	910,253
Balance at Mar. 31, 2019	$ 10,000	$ 9,103	219,992,719	(2,156)	(216,737,885)	3,271,781
Share-based payments			128,778			128,778
Foreign currency translation adjustments				(1,013)		(1,013)
Net loss					(1,436,921)	(1,436,921)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(465,191)	90,419
Issuance of common stock for conversion of Series A Preferred Stock	$ (4,652)	$ 904	3,748
Issuance of common stock for RSU exercises (in shares)		1,126
Issuance of common stock for RSU exercises		$ 11	(11)
Balance (in shares) at Jun. 30, 2019	534,809	1,001,798
Balance at Jun. 30, 2019	$ 5,348	$ 10,018	220,125,234	(3,169)	(218,174,806)	1,962,625
Share-based payments			294,600			294,600
Foreign currency translation adjustments				(4,501)		(4,501)
Net loss					(1,763,134)	(1,763,134)
Issuance of common stock for conversion of Series A Preferred Stock (in shares)	(334,809)	65,077
Issuance of common stock for conversion of Series A Preferred Stock	$ (3,348)	$ 651	2,697
Share rounding adjustment related to 1:20 reverse stock split (in shares)		6,117
Share rounding adjustment related to 1:20 reverse stock split		$ 61	(61)
Issuance of common stock and warrants from capital raises, net (in shares)		416,315
Issuance of common stock and warrants from capital raises, net		$ 4,163	6,548,679			6,552,842
Issuance of restricted stock awards (in shares)		15,688
Issuance of restricted stock awards		$ 157	(157)
Issuance of common stock for warrant exercises (in shares)		1,313,296
Issuance of common stock for warrant exercises		$ 13,133	(13,002)			131
Balance (in shares) at Sep. 30, 2019	200,000	2,818,291
Balance at Sep. 30, 2019	$ 2,000	$ 28,183	226,957,990	(7,670)	(219,937,940)	7,042,563
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Share-based payments			75,892			75,892
Foreign currency translation adjustments				(962)		(962)
Net loss					(7,575,218)	(7,575,218)
Issuance of common stock and inducement warrants for warrant exercises (in shares)		5,561,554
Issuance of common stock and inducement warrants for warrant exercises		$ 55,615	12,296,637			12,352,252
Balance (in shares) at Mar. 31, 2020	200,000	9,428,011
Balance at Mar. 31, 2020	$ 2,000	$ 94,280	239,439,587	(7,148)	(229,550,762)	9,977,957
Balance (in shares) at Dec. 31, 2019	200,000	3,866,457
Balance at Dec. 31, 2019	$ 2,000	$ 38,665	227,067,058	(6,186)	(221,975,544)	5,125,993
Net loss						(11,847,981)
Balance (in shares) at Sep. 30, 2020	200,000	17,295,703
Balance at Sep. 30, 2020	$ 2,000	$ 172,957	247,775,027	(3,986)	(233,823,525)	14,122,473
Balance (in shares) at Mar. 31, 2020	200,000	9,428,011
Balance at Mar. 31, 2020	$ 2,000	$ 94,280	239,439,587	(7,148)	(229,550,762)	9,977,957
Share-based payments			241,247			241,247
Foreign currency translation adjustments				(18)		(18)
Net loss					(1,950,941)	(1,950,941)
Issuance of common stock for RSU exercises (in shares)		563
Issuance of common stock for RSU exercises		$ 6	(6)
Issuance of common stock and warrants from capital raises, net (in shares)		5,000,000
Issuance of common stock and warrants from capital raises, net		$ 50,000	4,384,354			4,434,354
Issuance of common stock for warrant exercises (in shares)		2,871,296
Issuance of common stock for warrant exercises		$ 28,713	3,502,981			3,531,694
Forfeiture of restricted stock awards (in shares)		(4,167)
Forfeiture of restricted stock awards		$ (42)
Forfeiture of restricted stock awards			42
Balance (in shares) at Jun. 30, 2020	200,000	17,295,703
Balance at Jun. 30, 2020	$ 2,000	$ 172,957	247,568,205	(7,166)	(231,501,703)	16,234,293
Share-based payments			206,822			206,822
Foreign currency translation adjustments				3,180		3,180
Net loss					(2,321,822)	(2,321,822)
Balance (in shares) at Sep. 30, 2020	200,000	17,295,703
Balance at Sep. 30, 2020	$ 2,000	$ 172,957	$ 247,775,027	$ (3,986)	$ (233,823,525)	$ 14,122,473

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Parentheticals)	3 Months Ended
	Sep. 30, 2019
Reverse stock split	20

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net loss	$ (11,847,981)	$ (6,314,047)	$ (8,351,651)	$ (4,924,617)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	82,516	113,735	143,859	185,803
Share-based compensation expense	523,961	761,344	880,789	634,082
Allowance for bad debt		362,176	362,176
Warrant inducement expense	5,620,089
Gain on fair value of liability classified warrants	(39,642)	(416,796)	(499,138)	(3,269,148)
Changes in operating assets and liabilities:
Trade and other receivables	12,285	232,903	272,993	18,745
Prepaid expenses	(1,059,139)	(235,946)	(142,310)	32,303
ROU and other assets	24,207	24,938	39,643	(3,991)
Accounts payable and accrued expenses	(84,679)	340,673	(15,741)	(36,991)
Accrued bonuses	(36,936)		135,686	(418,625)
Other current liabilities	3,860	(48,110)	(47,414)	11,490
Lease and other long term liabilities	(29,089)	(27,618)	(34,572)	(1,876)
Net cash used in operating activities	(6,830,548)	(5,206,748)	(7,255,680)	(7,692,419)
Cash flows from investing activities:
Net cash provided by investing activities				4,998,286
Cash flows from financing activities:
Proceeds from sale of common stock, net	11,150,318	6,552,842
Proceeds from warrant exercises	3,547,894	131	236
Proceeds from short-term note payable		414,320	414,320	349,578
Payments of short-term note payable	(232,296)	(241,061)	(377,893)	(363,345)
Net cash provided by (used in) financing activities	14,465,916	6,726,232	6,589,505	1,814,233
Effects of exchange rates on cash	1,810	(6,758)	(6,018)	(7,930)
Net increase in cash and cash equivalents	7,637,178	1,512,726	(672,193)	(887,830)
Cash and cash equivalents, beginning of period	5,114,917	5,787,110	5,787,110	6,674,940
Cash and cash equivalents, end of period	12,752,095	7,299,836	5,114,917	5,787,110
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 14,015	$ 4,437	$ 8,920	$ 7,698

Note 1 - Organization and Busin

Note 1 - Organization and Business and Financial Condition	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Nature of Business In October 2019, one Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition and/or in-licensing of new science and technologies with the goal of developing and providing meaningful therapies for patients. Consequently, the Company plans to wind down its pre-clinical and clinical programs while seeking to out-license or partner NSI- 566 189 The Company was founded in 1997 On July 17, 2019, 1 20 1 20 Liquidity and Going Concern The Company has incurred losses since its inception and has not not no one not In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position at September 30, 2020, one 10 We expect that our existing cash and cash equivalents as of September 30, 2020 12 no not may third not Based upon our out-licensing strategy, we have greatly reduced our spending on the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates and have increased our spending on the evaluation of new assets and technologies with the goal of acquisition and/or development. No	Note 1. Organization and Business and Financial Condition Nature of Business In October 2019, one Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients. On October 31, 2019, January 10, 2020, not no In addition to the anticipated development of in-licensed or acquired technologies, the Company plans to continue to maintain NSI- 566 189 The Company was founded in 1997 may On July 17, 2019, 1 20 1 20 Liquidity and Going Concern The Company has incurred losses since its inception and has not not no one not Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position at December 31, 2019, one 10 We expect that our existing cash and cash equivalents as of December 31, 2019, January 12 -clinical and clinical development programs and to fund our operations. We anticipate raising additional capital through the private and public sales of our equity or debt securities, collaborative arrangements, licensing agreements or a combination thereof. Although management believes that such capital sources will be available, there can be no not may third not We have spent and will continue to spend substantial funds in the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates and we anticipate spending additional funds to maintain these programs as we seek partners to further their clinical development. We have also begun spending funds on the evaluation and new assets and technologies with the goal of acquisition and development. No

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies and Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Basis of Presentation In management's opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2019, not may not 10 December 31, 2019, may Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, trade and other receivables, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair values of our liability classified warrants were estimated using Level 3 3 Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for our subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Cash and cash equivalents at September 30, 2020 $12,651,700 $100,400 Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the nine September 30, 2020 2019, $58,900 $382,000, Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share or the three nine September 30, 2020 2019. 6.8 7.3 three nine September 30, 2020 2019, Share-Based Compensation We account for share-based compensation at fair value; accordingly, we expense the estimated fair value of share-based awards over the requisite service period. Share-based compensation cost for stock options and warrants is generally determined at the grant date using an option pricing model. Option pricing models require us to make assumptions, including expected volatility and expected term of the options. If any of the assumptions we use in the model were to significantly change, share-based compensation expense may Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No nine September 30, 2020 2019. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” Leases We determine if an arrangement is or contains a lease at its inception. We have made accounting policy elections whereby we (i) do not 12 not ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. See Note 5, Significant New Accounting Pronouncements Recently Adopted Guidance In August 2018, ASU 2018 13, 820 December 15, 2019. January 1, 2020. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2020, ASU No. 2020 06, 470 20 815 40 December 15, 2023, may not We have reviewed other recent accounting pronouncements and concluded that they are either not no	Note 2. Basis of Presentation Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness was estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities and approximates the carrying value. The fair values of our liability classified warrants were estimated using Level 3 3 Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the years ended December 31, 2019 2018, $459,000 $538,000, Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the years ended December 31, 2019 2018. 7.3 0.6 December 31, 2019 2018, Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and stock purchase warrants granted to employees and board members is generally determined at the grant date while awards granted to non-employee consultants are generally valued at the vesting date using an option pricing model that uses Level 3 Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No December 31, 2019 2018. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” Significant New Accounting Pronouncements Recently Adopted Guidance In February 2016, ASU, No. 2016 02, December 15, 2018 may January 1, 2019 not not $53,000 $75,700 In June 2018, ASU 2018 07, ASC 718, 1 2 3 December 15, 2018. January 1, 2019. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2018, ASU 2018 13, 820 December 15, 2019 not In August 2018, ASU 2018 15, December 15, 2019 not We have reviewed other recent accounting pronouncements and concluded that they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: · Level 1 · Level 2 not · Level 3 Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. At September 30, 2020 December 31, 2019, May 2016 August 2017 4 3 Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ – $ – $ 84,596 $ 84,596 Balance at December 31, 2019 $ – $ – $ 84,596 $ 84,596 Liability classified stock purchase warrants $ – $ – $ 44,954 $ 44,954 Balance at September 30, 2020 $ – $ – $ 44,954 $ 44,954 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 Mark-to-market liabilities - Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 Balance at December 31, 2019 $ 84,596 Change in fair value - gain (39,642 ) Balance at September 30, 2020 $ 44,954 The (gains) losses resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may For the nine September 30, 2020, May 2020 nine September 30, 2019,	Note 3. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: Level 1 inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not Level 3 inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value on a recurring into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. At December 31, 2019 December 31, 2018, May 2016 August 2017 4 3 Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 84,596 $ 84,596 Balance at December 31, 2019 $ - $ - $ 84,596 $ 84,596 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 December 31, 2019: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (499,138 ) Balance at December 31, 2019 $ 84,596 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 December 31, 2018: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (3,269,148 ) Balance at December 31, 2018 $ 583,734 The gains resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying consolidated statements of operations. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may

Note 4 - Stockholders' Equity

Note 4 - Stockholders' Equity	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 4. We have granted share-based compensation awards to employees, board members and service providers. Awards may ten September 30, 2020, 7.1 We typically record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expenses included in our condensed consolidated statements of operations and comprehensive loss are as follows: Three Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ – General and administrative expenses 180,571 294,600 Total $ 206,822 $ 294,600 Nine Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ 200,337 General and administrative expenses 497,710 561,007 Total $ 523,961 $ 761,344 Stock Options A summary of stock option activity and related information for the nine September 30, 2020 Number of Options Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2020 271,660 $ 61.83 7.8 $ – Granted 1,686,466 $ 0.62 Exercised – $ – $ – Forfeited (157,204 ) $ 15.53 Outstanding at September 30, 2020 1,800,922 $ 8.55 9.3 $ – Exercisable at September 30, 2020 710,884 $ 20.63 8.9 $ – Range of Exercise Prices Number of Options Weighted-Average Weighted-Average Aggregate $0.62 1,686,466 $ 0.62 9.5 $ – $5.90 - $6.00 45,378 $ 5.99 8.8 – $7.20 - $8.80 6,380 $ 8.69 8.4 – $22.20 - $80.60 24,488 $ 31.15 4.8 – $107.40 - $1,102.40 38,210 $ 347.18 2.0 – 1,800,922 $ 8.55 9.3 $ – The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. The Company generally uses the “simplified method” to estimate expected life. Significant assumptions used in these models include: Nine Months Ended September 30, 2020 2019 Annual dividend - - Expected life (in years) 4.0 - 5.2 4.8 - 5.5 Risk free interest rate 0.2% - 0.3% 1.8% - 2.5% Expected volatility 110% - 111% 97% - 115% Options granted in the nine September 30, 2020 2019, $0.52 $3.45 Unrecognized compensation cost for unvested stock option awards outstanding at September 30, 2020 $587,000 2.5 In 2019, $102,000 nine September 30, 2019. RSUs We have granted restricted stock units (RSUs) to certain employees and board members that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSUs. The grant date fair value of RSUs is based upon the market price of the underlying common stock on the date of grant. We granted 24,000 4,904 nine September 30, 2020 2019, RSUs vesting in the nine September 30, 2020 2019 $23,400 $6,400, At September 30, 2020, 28,904 $1.58 $16,800. September 30, 2020 $8,000 0.5 In the nine September 30, 2020, 563 $300 nine September 30, 2019, 1,126 $10,400 Restricted Stock We have granted restricted stock to certain board members that vest quarterly over the grant year. The grant date fair value of the restricted stock is based upon the market price of the common stock on the date of grant. No nine September 30, 2020. nine September 30, 2019, 15,688 $5.95. Restricted stock vesting in the nine September 30, 2020, $5.90 $2,600. nine September 30, 2019, $9.73 $14,500. No September 30, 2020. Stock Purchase Warrants. We have issued warrants to purchase common stock to certain officers, directors, stockholders and service providers as well as in conjunction with debt and equity offerings and at various times replacement warrants were issued as an inducement for warrant exercises. In May 2016 August 2017, 87,309 112,500 September 30, 2020, 149,136 3 $0.90 May 2020 In January 2020, 5,555,554 $1.36 $7.6 $2.70 $1.36 5,555,554 $1.23 2,777,777 two 2,777,777 five 444,445 $1.70 five We recognized an expense in the accompanying condensed consolidated statement of operations for the nine September 30, 2020 $5.6 In conjunction with our May 2020 400,000 $1.25 five A summary of outstanding warrants at September 30, 2020 Range of Exercise Prices Number of Range of Expiration Dates $0.90 - $1.25 3,233,407 May 2021 - May 2025 $1.70 - $3.38 1,493,999 December 2020 - January 2025 $6.00 - $782.60 199,337 October 2020 - April 2024 4,926,743 Preferred and Common Stock We have outstanding 200,000 4.5% December 2016. 4.5% 38,873 April July 2019, 800,000 4.5% 155,496 In May 2020, 5,000,000 $1.00 $5.0 $4.4 3 no. 333 218608 400,000 $1.25 5	Note 4. We have granted share-based compensation awards to employees, board members and service providers. In addition, we have issued warrants to purchase common stock in conjunction with debt and equity offerings. Awards may ten December 31, 2019, 7,441,532 We record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expense included in the statements of operations was as follows: Year Ended December 31, 2019 2018 Research and development costs $ 200,337 $ 133,334 General and administrative expenses 680,452 500,748 Total $ 880,789 $ 634,082 Stock Options A summary of stock option activity and related information for the year ended December 31, 2019 Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 $ - Exercised - - Forfeited/Expired (38,197 ) $ 67.90 Outstanding at December 31, 2019 271,660 $ 61.83 7.8 $ - Exercisable at December 31, 2019 207,813 $ 78.30 7.4 $ - Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 55,484 $ 5.99 9.5 $ - $7.20 - $8.80 146,972 $ 8.51 9.0 - $22.20 - $99.20 28,501 $ 31.63 5.7 - $107.40 - $1,102.41 40,703 $ 351.63 2.8 - 271,660 $ 61.83 7.8 $ - The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include: Year Ended December 31, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.5% - 2.8% Expected volatility 97% - 115% 97% - 113% Options granted in the years ended December 31, 2019 2018 $3.45 $9.40, December 31, 2019 2018 $671,100 $205,000, Unrecognized compensation cost for unvested stock option awards outstanding at December 31, 2019 $155,000 0.6 In the three March 31, 2019, $102,000 three March 31, 2019. RSUs We have granted restricted stock units (RSU's) that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSU's and the holders' ability to transfer the shares received upon exercise. The fair value of RSU's granted is based upon the market price of the underlying common stock as if they were vested and issued on the date of grant. A summary of our RSU activity for the year ended December 31, 2019 Number of RSU's Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 2,816 $ 64.80 Granted 4,904 $ 5.90 Exercised and converted to common shares (1,127 ) $ 22.20 Forfeited (1,126 ) $ 22.20 Outstanding at December 31, 2019 5,467 $ 29.62 Exercisable at December 31, 2019 2,925 $ 50.23 The total intrinsic value of the outstanding RSU's at December 31, 2019 $5,400. December 31, 2019 2018, $13,900 $50,000, December 31, 2019 $10,400. No December 31, 2018. Unrecognized compensation cost for unvested RSU's outstanding at December 31, 2019 $15,000 0.5 Restricted Stock We have granted restricted stock to certain board members. A summary of our restricted stock activity for the year ended December 31, 2019 Shares of Restricted Stock Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 1,127 $ 22.20 Granted 15,689 $ 5.95 Vested (8,835 ) $ 8.03 Forfeited - $ - Outstanding at December 31, 2019 7,981 $ 5.95 The December 31, 2019 $7,900. December 31, 2019 $18,500. Unrecognized compensation cost for unvested restricted stock outstanding at December 31, 2019 $47,500 0.5 Stock Purchase Warrants We have issued warrants to purchase common stock to certain officers, directors, stockholders and service providers as well as in conjunction with debt and equity offerings and at various times replacement warrants were issued as an inducement for warrant exercises. In May 2016 August 2017, 87,309 112,500 December 31, 2019, 149,136 3 In February 2019, 25,000 third $6.00, January 2024 $3.80 25% 75% September 30, 2019. no 2.5 2.5% 110%. In July 2019, 3,194,443 $2.70 December 31, 2020; ( 3,194,443 $2.70 5 2,361,462 $0.0001 no December 31, 2019, $200 In connection with the July 222,223 $3.375 5 A summary of outstanding warrants at December 31, 2019 Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 24,650 March 2020 - July 2023 6,968,908 In January 2020, 5,555,554 $1.36 $7.6 $2.70 $1.36 5,555,554 $1.23 2,777,777 two 2,777,777 five 444,445 $1.70 five Preferred and Common Stock We have outstanding 200,000 4.5% December 2016. 4.5% 38,873 April July 2019, 800,000 4.5% 155,496 In July 2019, 416,315 2,361,462 $2.70 $7.5 one one one one one one $0.0001 $2.70 December 31, 2020 five $6.6 416,666 416,666 1 no. 333 232273

Note 5 - Property and Equipment

Note 5 - Property and Equipment	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 5. The major classes of property and equipment December 31: 2019 2018 Furniture and fixtures $ 35,407 $ 35,407 Computers and office equipment 138,897 138,897 Lab equipment 817,149 818,267 991,453 992,571 Less accumulated depreciation (950,417 ) (902,260 ) Property and equipment, net $ 41,036 $ 90,311 The above includes approximately $70,000 December 31, 2019 2018, $49,000 $84,000,

Note 6 - Patents

Note 6 - Patents	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 6. The Company holds patents related to its stem cell and small molecule technologies. Patent costs are capitalized and are being amortized over the life of the patents. The weighted average remaining unamortized life of issued patents was approximately 8.6 December 31, 2019. may not not December 31, 2019 2018, no December 31: 2019 2018 Patent asset $ 2,006,443 $ 2,006,443 Accumulated amortization (1,337,507 ) (1,242,900 ) Net intangibles $ 668,936 $ 763,543 Amortization expense for the years ended December 31, 2019 2018 $95,000 $102,000, five $75,000

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 7. Our provision for income taxes for the years ended December 31, 2019 2018 2019 2018 Current provision: Federal $ - $ - State - - Foreign - - Total current provision - - Deferred provision (benefit): Federal (545,792 ) 7,726 State 1,001,786 (2,749,386 ) Foreign - - Total deferred provision (benefit) 455,994 (2,741,660 ) Valuation allowance (455,994 ) 2,741,660 Consolidated income tax provision $ - $ - We provide a full valuation allowance on our net deferred tax assets because management has determined that it is more likely than not not The difference between income taxes computed by applying the statutory federal income tax rate to consolidated losses before income taxes and the consolidated provision for income taxes is attributable to the following: 2019 2018 Federal statutory rate (21.0 %) (21.0 %) State income taxes, net of Federal benefits (5.3 %) (5.0 %) Rate changes (6.4 %) (66.3 %) Change in fair value of liability classified warrants (1.6 %) (17.3 %) Other, including non-deductible expenses 28.8 % 53.9 % Valuation allowance 5.5 % 55.7 % Total 0.0 % 0.0 % The tax effects of significant temporary differences representing deferred tax assets as of December 31 2019 2018 Net operating loss carryforwards $ 43,190,604 $ 42,580,533 Stock based compensation expense 2,605,277 2,643,471 Tax credit carryforwards and other 889,372 1,005,255 Gross deferred tax assets 46,685,253 46,229,259 Valuation allowance (46,685,253 ) (46,229,259 ) Net deferred tax assets $ - $ - The Company had Federal net operating loss (“NOL”) carryforwards of approximately $160 December 31, 2019 $146 2018 2019. 2020. may may not not 2016.

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5. Leases We currently operate one one Our corporate offices and primary research facilities are located in Germantown, Maryland, where we lease approximately 1,500 $5,600 12 December 31, 2020. not We also lease approximately 11,300 September 2019, $4,400 September 2024 first Our long-term operating lease and related sublease for our San Diego facility both terminated in August 2019. $86,100 nine September 30, 2019. We recognized total rent expense of approximately $91,100 $164,500 nine September 30, 2020 2019, $50,700 $83,900 nine September 30, 2020 2019, nine September 30 2020 2019 Operating lease cost $ 91,100 $ 141,300 Variable lease cost – 23,200 Sublease income – (86,100 ) Total net lease cost $ 91,100 $ 78,400 At September 30, 2020, $181,800 $159,400 Future payments under our lone long-term operating lease as of September 30, 2020 Future undiscounted cash flows: 2020 * $ 12,200 2021 55,900 2022 57,600 2023 59,400 2024 14,000 Total 199,100 Discount factor (39,700 ) Lease liability 159,400 Less current liability (37,100 ) Non-current lease liability $ 122,300 * reflects the remaining 3 2020 Other From time to time, we are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business. We are currently not	Note 8. Leases We currently operate one one Our corporate offices and primary research facilities are located in Germantown, Maryland, where we lease approximately 1,500 $5,700 12 December 31, 2019. not We also lease approximately 11,300 September 2019, $4,400 September 2024 first $205,000. Our long-term operating lease and related sublease for our San Diego facility both terminated in August 2019. $86,100 December 31, 2019. We recognized total rent expense of approximately $194,200 $164,000 December 31, 2019 2018, 2019 $67,700 December 31, 2019 Operating lease cost $171,000 Variable lease cost 23,200 Sublease income (86,100) Total net lease cost $108,100 In the year ended December 31, 2019, $204,300 At December 31, 2019, $201,700 $180,900 12.75%. Maturities of our lone long-term operating lease as of December 31, 2019 Future undiscounted cash flows: 2020 $ 53,503 2021 54,539 2022 56,190 2023 58,027 2024 13,650 Total 235,909 Discount factor (54,997 ) Lease liability 180,912 Less current liability (32,369 ) Non-current lease liability $ 148,543 Other From time to time, we are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business. We are currently not

Note 9 - Related Party Receivab

Note 9 - Related Party Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6. On August 10, 2016, six $658,000 The $658,000 $199,000 In March 2019, 50% $229,000 September 30, 2020, $229,000 July 2025. not	Note 9. On August 10, 2016, six $658,000 The $658,000 $199,000 In March 2019, 50% $229,000 December 31, 2019, $229,000 July 2025. not

Note 10 - Subsequent Events

Note 10 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8. None.	Note 10. In January 2020, 5,555,554 $1.36 $7.6 4 On March 23, 2020, 500,000 715,000 In December 2019

Note 1 - Organization, Business

Note 1 - Organization, Business and Financial Condition	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Nature of Business In October 2019, one Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition and/or in-licensing of new science and technologies with the goal of developing and providing meaningful therapies for patients. Consequently, the Company plans to wind down its pre-clinical and clinical programs while seeking to out-license or partner NSI- 566 189 The Company was founded in 1997 On July 17, 2019, 1 20 1 20 Liquidity and Going Concern The Company has incurred losses since its inception and has not not no one not In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position at September 30, 2020, one 10 We expect that our existing cash and cash equivalents as of September 30, 2020 12 no not may third not Based upon our out-licensing strategy, we have greatly reduced our spending on the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates and have increased our spending on the evaluation of new assets and technologies with the goal of acquisition and/or development. No	Note 1. Organization and Business and Financial Condition Nature of Business In October 2019, one Seneca Biopharma, Inc., is a clinical-stage biopharmaceutical company developing novel treatments for various diseases of high unmet medical need. The Company is in the process of transforming the organization through the acquisition or in-licensing of new science and technologies, to develop with the goal of providing meaningful therapies for patients. On October 31, 2019, January 10, 2020, not no In addition to the anticipated development of in-licensed or acquired technologies, the Company plans to continue to maintain NSI- 566 189 The Company was founded in 1997 may On July 17, 2019, 1 20 1 20 Liquidity and Going Concern The Company has incurred losses since its inception and has not not no one not Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position at December 31, 2019, one 10 We expect that our existing cash and cash equivalents as of December 31, 2019, January 12 -clinical and clinical development programs and to fund our operations. We anticipate raising additional capital through the private and public sales of our equity or debt securities, collaborative arrangements, licensing agreements or a combination thereof. Although management believes that such capital sources will be available, there can be no not may third not We have spent and will continue to spend substantial funds in the research, development, pre-clinical and clinical testing of our small molecule and stem cell product candidates and we anticipate spending additional funds to maintain these programs as we seek partners to further their clinical development. We have also begun spending funds on the evaluation and new assets and technologies with the goal of acquisition and development. No

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies and Basis of Presentation	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Basis of Presentation In management's opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2019, not may not 10 December 31, 2019, may Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, trade and other receivables, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair values of our liability classified warrants were estimated using Level 3 3 Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for our subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Cash and cash equivalents at September 30, 2020 $12,651,700 $100,400 Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the nine September 30, 2020 2019, $58,900 $382,000, Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share or the three nine September 30, 2020 2019. 6.8 7.3 three nine September 30, 2020 2019, Share-Based Compensation We account for share-based compensation at fair value; accordingly, we expense the estimated fair value of share-based awards over the requisite service period. Share-based compensation cost for stock options and warrants is generally determined at the grant date using an option pricing model. Option pricing models require us to make assumptions, including expected volatility and expected term of the options. If any of the assumptions we use in the model were to significantly change, share-based compensation expense may Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No nine September 30, 2020 2019. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” Leases We determine if an arrangement is or contains a lease at its inception. We have made accounting policy elections whereby we (i) do not 12 not ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. See Note 5, Significant New Accounting Pronouncements Recently Adopted Guidance In August 2018, ASU 2018 13, 820 December 15, 2019. January 1, 2020. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2020, ASU No. 2020 06, 470 20 815 40 December 15, 2023, may not We have reviewed other recent accounting pronouncements and concluded that they are either not no	Note 2. Basis of Presentation Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates. Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness was estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities and approximates the carrying value. The fair values of our liability classified warrants were estimated using Level 3 3 Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss. Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit. Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the years ended December 31, 2019 2018, $459,000 $538,000, Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the years ended December 31, 2019 2018. 7.3 0.6 December 31, 2019 2018, Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and stock purchase warrants granted to employees and board members is generally determined at the grant date while awards granted to non-employee consultants are generally valued at the vesting date using an option pricing model that uses Level 3 Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No December 31, 2019 2018. Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not” Significant New Accounting Pronouncements Recently Adopted Guidance In February 2016, ASU, No. 2016 02, December 15, 2018 may January 1, 2019 not not $53,000 $75,700 In June 2018, ASU 2018 07, ASC 718, 1 2 3 December 15, 2018. January 1, 2019. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2018, ASU 2018 13, 820 December 15, 2019 not In August 2018, ASU 2018 15, December 15, 2019 not We have reviewed other recent accounting pronouncements and concluded that they are either not no

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements 1	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 3. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: · Level 1 · Level 2 not · Level 3 Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. At September 30, 2020 December 31, 2019, May 2016 August 2017 4 3 Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ – $ – $ 84,596 $ 84,596 Balance at December 31, 2019 $ – $ – $ 84,596 $ 84,596 Liability classified stock purchase warrants $ – $ – $ 44,954 $ 44,954 Balance at September 30, 2020 $ – $ – $ 44,954 $ 44,954 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 Mark-to-market liabilities - Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 Balance at December 31, 2019 $ 84,596 Change in fair value - gain (39,642 ) Balance at September 30, 2020 $ 44,954 The (gains) losses resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may For the nine September 30, 2020, May 2020 nine September 30, 2019,	Note 3. Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These levels are: Level 1 inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not Level 3 inputs are generally unobservable and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis We have segregated our financial assets and liabilities that are measured at fair value on a recurring into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date. At December 31, 2019 December 31, 2018, May 2016 August 2017 4 3 Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 84,596 $ 84,596 Balance at December 31, 2019 $ - $ - $ 84,596 $ 84,596 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 December 31, 2019: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (499,138 ) Balance at December 31, 2019 $ 84,596 The following table presents the activity for those items measured at fair value on a recurring basis using Level 3 December 31, 2018: Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (3,269,148 ) Balance at December 31, 2018 $ 583,734 The gains resulting from the changes in the fair value of the liability classified warrants are classified as other income or expense in the accompanying consolidated statements of operations. The fair value of the common stock purchase warrants is determined based on the Black-Scholes option pricing model or other option pricing models as appropriate and includes the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may

Note 4 - Stockholders' Equity 1

Note 4 - Stockholders' Equity 1	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 4. We have granted share-based compensation awards to employees, board members and service providers. Awards may ten September 30, 2020, 7.1 We typically record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expenses included in our condensed consolidated statements of operations and comprehensive loss are as follows: Three Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ – General and administrative expenses 180,571 294,600 Total $ 206,822 $ 294,600 Nine Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ 200,337 General and administrative expenses 497,710 561,007 Total $ 523,961 $ 761,344 Stock Options A summary of stock option activity and related information for the nine September 30, 2020 Number of Options Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2020 271,660 $ 61.83 7.8 $ – Granted 1,686,466 $ 0.62 Exercised – $ – $ – Forfeited (157,204 ) $ 15.53 Outstanding at September 30, 2020 1,800,922 $ 8.55 9.3 $ – Exercisable at September 30, 2020 710,884 $ 20.63 8.9 $ – Range of Exercise Prices Number of Options Weighted-Average Weighted-Average Aggregate $0.62 1,686,466 $ 0.62 9.5 $ – $5.90 - $6.00 45,378 $ 5.99 8.8 – $7.20 - $8.80 6,380 $ 8.69 8.4 – $22.20 - $80.60 24,488 $ 31.15 4.8 – $107.40 - $1,102.40 38,210 $ 347.18 2.0 – 1,800,922 $ 8.55 9.3 $ – The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. The Company generally uses the “simplified method” to estimate expected life. Significant assumptions used in these models include: Nine Months Ended September 30, 2020 2019 Annual dividend - - Expected life (in years) 4.0 - 5.2 4.8 - 5.5 Risk free interest rate 0.2% - 0.3% 1.8% - 2.5% Expected volatility 110% - 111% 97% - 115% Options granted in the nine September 30, 2020 2019, $0.52 $3.45 Unrecognized compensation cost for unvested stock option awards outstanding at September 30, 2020 $587,000 2.5 In 2019, $102,000 nine September 30, 2019. RSUs We have granted restricted stock units (RSUs) to certain employees and board members that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSUs. The grant date fair value of RSUs is based upon the market price of the underlying common stock on the date of grant. We granted 24,000 4,904 nine September 30, 2020 2019, RSUs vesting in the nine September 30, 2020 2019 $23,400 $6,400, At September 30, 2020, 28,904 $1.58 $16,800. September 30, 2020 $8,000 0.5 In the nine September 30, 2020, 563 $300 nine September 30, 2019, 1,126 $10,400 Restricted Stock We have granted restricted stock to certain board members that vest quarterly over the grant year. The grant date fair value of the restricted stock is based upon the market price of the common stock on the date of grant. No nine September 30, 2020. nine September 30, 2019, 15,688 $5.95. Restricted stock vesting in the nine September 30, 2020, $5.90 $2,600. nine September 30, 2019, $9.73 $14,500. No September 30, 2020. Stock Purchase Warrants. We have issued warrants to purchase common stock to certain officers, directors, stockholders and service providers as well as in conjunction with debt and equity offerings and at various times replacement warrants were issued as an inducement for warrant exercises. In May 2016 August 2017, 87,309 112,500 September 30, 2020, 149,136 3 $0.90 May 2020 In January 2020, 5,555,554 $1.36 $7.6 $2.70 $1.36 5,555,554 $1.23 2,777,777 two 2,777,777 five 444,445 $1.70 five We recognized an expense in the accompanying condensed consolidated statement of operations for the nine September 30, 2020 $5.6 In conjunction with our May 2020 400,000 $1.25 five A summary of outstanding warrants at September 30, 2020 Range of Exercise Prices Number of Range of Expiration Dates $0.90 - $1.25 3,233,407 May 2021 - May 2025 $1.70 - $3.38 1,493,999 December 2020 - January 2025 $6.00 - $782.60 199,337 October 2020 - April 2024 4,926,743 Preferred and Common Stock We have outstanding 200,000 4.5% December 2016. 4.5% 38,873 April July 2019, 800,000 4.5% 155,496 In May 2020, 5,000,000 $1.00 $5.0 $4.4 3 no. 333 218608 400,000 $1.25 5	Note 4. We have granted share-based compensation awards to employees, board members and service providers. In addition, we have issued warrants to purchase common stock in conjunction with debt and equity offerings. Awards may ten December 31, 2019, 7,441,532 We record share-based compensation expense on a straight-line basis over the requisite service period. Share-based compensation expense included in the statements of operations was as follows: Year Ended December 31, 2019 2018 Research and development costs $ 200,337 $ 133,334 General and administrative expenses 680,452 500,748 Total $ 880,789 $ 634,082 Stock Options A summary of stock option activity and related information for the year ended December 31, 2019 Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 $ - Exercised - - Forfeited/Expired (38,197 ) $ 67.90 Outstanding at December 31, 2019 271,660 $ 61.83 7.8 $ - Exercisable at December 31, 2019 207,813 $ 78.30 7.4 $ - Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 55,484 $ 5.99 9.5 $ - $7.20 - $8.80 146,972 $ 8.51 9.0 - $22.20 - $99.20 28,501 $ 31.63 5.7 - $107.40 - $1,102.41 40,703 $ 351.63 2.8 - 271,660 $ 61.83 7.8 $ - The Company uses the Black-Scholes option pricing model for “plain vanilla” options and other pricing models as appropriate to calculate the fair value of options. Significant assumptions used in these models include: Year Ended December 31, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.5% - 2.8% Expected volatility 97% - 115% 97% - 113% Options granted in the years ended December 31, 2019 2018 $3.45 $9.40, December 31, 2019 2018 $671,100 $205,000, Unrecognized compensation cost for unvested stock option awards outstanding at December 31, 2019 $155,000 0.6 In the three March 31, 2019, $102,000 three March 31, 2019. RSUs We have granted restricted stock units (RSU's) that entitle the holders to receive shares of our common stock upon vesting and subject to certain restrictions regarding the exercise of the RSU's and the holders' ability to transfer the shares received upon exercise. The fair value of RSU's granted is based upon the market price of the underlying common stock as if they were vested and issued on the date of grant. A summary of our RSU activity for the year ended December 31, 2019 Number of RSU's Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 2,816 $ 64.80 Granted 4,904 $ 5.90 Exercised and converted to common shares (1,127 ) $ 22.20 Forfeited (1,126 ) $ 22.20 Outstanding at December 31, 2019 5,467 $ 29.62 Exercisable at December 31, 2019 2,925 $ 50.23 The total intrinsic value of the outstanding RSU's at December 31, 2019 $5,400. December 31, 2019 2018, $13,900 $50,000, December 31, 2019 $10,400. No December 31, 2018. Unrecognized compensation cost for unvested RSU's outstanding at December 31, 2019 $15,000 0.5 Restricted Stock We have granted restricted stock to certain board members. A summary of our restricted stock activity for the year ended December 31, 2019 Shares of Restricted Stock Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 1,127 $ 22.20 Granted 15,689 $ 5.95 Vested (8,835 ) $ 8.03 Forfeited - $ - Outstanding at December 31, 2019 7,981 $ 5.95 The December 31, 2019 $7,900. December 31, 2019 $18,500. Unrecognized compensation cost for unvested restricted stock outstanding at December 31, 2019 $47,500 0.5 Stock Purchase Warrants We have issued warrants to purchase common stock to certain officers, directors, stockholders and service providers as well as in conjunction with debt and equity offerings and at various times replacement warrants were issued as an inducement for warrant exercises. In May 2016 August 2017, 87,309 112,500 December 31, 2019, 149,136 3 In February 2019, 25,000 third $6.00, January 2024 $3.80 25% 75% September 30, 2019. no 2.5 2.5% 110%. In July 2019, 3,194,443 $2.70 December 31, 2020; ( 3,194,443 $2.70 5 2,361,462 $0.0001 no December 31, 2019, $200 In connection with the July 222,223 $3.375 5 A summary of outstanding warrants at December 31, 2019 Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 24,650 March 2020 - July 2023 6,968,908 In January 2020, 5,555,554 $1.36 $7.6 $2.70 $1.36 5,555,554 $1.23 2,777,777 two 2,777,777 five 444,445 $1.70 five Preferred and Common Stock We have outstanding 200,000 4.5% December 2016. 4.5% 38,873 April July 2019, 800,000 4.5% 155,496 In July 2019, 416,315 2,361,462 $2.70 $7.5 one one one one one one $0.0001 $2.70 December 31, 2020 five $6.6 416,666 416,666 1 no. 333 232273

Note 5 - Commitments and Contin

Note 5 - Commitments and Contingencies	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 5. Leases We currently operate one one Our corporate offices and primary research facilities are located in Germantown, Maryland, where we lease approximately 1,500 $5,600 12 December 31, 2020. not We also lease approximately 11,300 September 2019, $4,400 September 2024 first Our long-term operating lease and related sublease for our San Diego facility both terminated in August 2019. $86,100 nine September 30, 2019. We recognized total rent expense of approximately $91,100 $164,500 nine September 30, 2020 2019, $50,700 $83,900 nine September 30, 2020 2019, nine September 30 2020 2019 Operating lease cost $ 91,100 $ 141,300 Variable lease cost – 23,200 Sublease income – (86,100 ) Total net lease cost $ 91,100 $ 78,400 At September 30, 2020, $181,800 $159,400 Future payments under our lone long-term operating lease as of September 30, 2020 Future undiscounted cash flows: 2020 * $ 12,200 2021 55,900 2022 57,600 2023 59,400 2024 14,000 Total 199,100 Discount factor (39,700 ) Lease liability 159,400 Less current liability (37,100 ) Non-current lease liability $ 122,300 * reflects the remaining 3 2020 Other From time to time, we are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business. We are currently not	Note 8. Leases We currently operate one one Our corporate offices and primary research facilities are located in Germantown, Maryland, where we lease approximately 1,500 $5,700 12 December 31, 2019. not We also lease approximately 11,300 September 2019, $4,400 September 2024 first $205,000. Our long-term operating lease and related sublease for our San Diego facility both terminated in August 2019. $86,100 December 31, 2019. We recognized total rent expense of approximately $194,200 $164,000 December 31, 2019 2018, 2019 $67,700 December 31, 2019 Operating lease cost $171,000 Variable lease cost 23,200 Sublease income (86,100) Total net lease cost $108,100 In the year ended December 31, 2019, $204,300 At December 31, 2019, $201,700 $180,900 12.75%. Maturities of our lone long-term operating lease as of December 31, 2019 Future undiscounted cash flows: 2020 $ 53,503 2021 54,539 2022 56,190 2023 58,027 2024 13,650 Total 235,909 Discount factor (54,997 ) Lease liability 180,912 Less current liability (32,369 ) Non-current lease liability $ 148,543 Other From time to time, we are parties to legal proceedings that we believe to be ordinary, routine litigation incidental to the business. We are currently not

Note 6 - Related Party Receivab

Note 6 - Related Party Receivable	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 6. On August 10, 2016, six $658,000 The $658,000 $199,000 In March 2019, 50% $229,000 September 30, 2020, $229,000 July 2025. not	Note 9. On August 10, 2016, six $658,000 The $658,000 $199,000 In March 2019, 50% $229,000 December 31, 2019, $229,000 July 2025. not

Note 7 - Disposal Group Assets

Note 7 - Disposal Group Assets Held for Sale	9 Months Ended
	Sep. 30, 2020
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 7. At September 30, 2020, third 566 one September 30, 2020. no no no Based on current negotiations, the Company concluded the net proceeds from the sale are expected to exceed the net carrying value of the assets and liabilities and accordingly, no September 30, 2020. The assets and liabilities classified as a disposal group held for sale are comprised of the following: September 30, 2020 Cash $ 100,367 Prepaid expesnes 143,836 Property and equipment, net 1,080 Patents, net 458,738 ROU and other assets 195,517 Disposal group assets held for sale $ 899,538 Accounts payable and accrued expenses $ 166,373 Lease liabilities 159,439 Disposal group liabilities associated with assets held for sale $ 325,812

Note 8 - Subsequent Events

Note 8 - Subsequent Events	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8. None.	Note 10. In January 2020, 5,555,554 $1.36 $7.6 4 On March 23, 2020, 500,000 715,000 In December 2019

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation In management's opinion, the accompanying interim unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The unaudited condensed consolidated balance sheet at December 31, 2019, not may not 10 December 31, 2019, may	Basis of Presentation Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The financial statements include the accounts of the Company and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The unaudited condensed consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, trade and other receivables, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair values of our liability classified warrants were estimated using Level 3 3	Fair Value Measurements The carrying amounts of our short-term financial instruments, which primarily include cash and cash equivalents, short-term investments, accounts payable and accrued expenses, approximate their fair values due to their short maturities. The fair value of our long-term indebtedness was estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities and approximates the carrying value. The fair values of our liability classified warrants were estimated using Level 3 3
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for our subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.	Foreign Currency Translation The functional currency of our wholly owned foreign subsidiary is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on exchange rates at the end of the reporting period; income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiary are accumulated in other comprehensive income or loss, a component of stockholders' equity. Transaction gains or losses are included in the determination of net loss.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not Cash and cash equivalents at September 30, 2020 $12,651,700 $100,400	Cash, Cash Equivalents and Credit Risk Cash equivalents consist of investments in low risk, highly liquid money market accounts and certificates of deposit with original maturities of 90 may Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents. Our investment policy, approved by our Board of Directors, limits the amount we may one not
Revenue from Contract with Customer [Policy Text Block]	Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.	Revenue The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers; (ii) identification of distinct performance obligations in the contract; (iii) determination of contract transaction price; (iv) allocation of contract transaction price to the performance obligations; and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation. The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to customers) in an amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. Deferred revenue results from cash receipts from or amounts billed to customers in advance of the transfer of control of the promised services to the customer and is recognized as performance obligations are satisfied. When sales commissions or other costs to obtain contracts with customers are considered incremental and recoverable, those costs are deferred and then amortized as selling and marketing expenses on a straight-line basis over an estimated period of benefit.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the nine September 30, 2020 2019, $58,900 $382,000,	Research and Development Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of costs associated with the pre-clinical development and clinical trials of our product candidates. For the years ended December 31, 2019 2018, $459,000 $538,000,
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share or the three nine September 30, 2020 2019. 6.8 7.3 three nine September 30, 2020 2019,	Income (Loss) per Common Share Basic income (loss) per common share is computed by dividing total net income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. For periods of net income when the effects are dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding and the dilutive impact of all dilutive potential common shares. Dilutive potential common shares consist primarily of convertible preferred stock, stock options, restricted stock units and common stock purchase warrants. The dilutive impact of potential common shares resulting from common stock equivalents is determined by applying the treasury stock method. Our unvested restricted shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; the calculation of basic and diluted income per share excludes net income attributable to the unvested restricted shares from the numerator and excludes the impact of the shares from the denominator. For all periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive due to the net losses; accordingly, diluted loss per share is the same as basic loss per share for the years ended December 31, 2019 2018. 7.3 0.6 December 31, 2019 2018,
Share-based Payment Arrangement [Policy Text Block]	Share-Based Compensation We account for share-based compensation at fair value; accordingly, we expense the estimated fair value of share-based awards over the requisite service period. Share-based compensation cost for stock options and warrants is generally determined at the grant date using an option pricing model. Option pricing models require us to make assumptions, including expected volatility and expected term of the options. If any of the assumptions we use in the model were to significantly change, share-based compensation expense may	Share-Based Compensation We account for share-based compensation at fair value. Share-based compensation cost for stock options and stock purchase warrants granted to employees and board members is generally determined at the grant date while awards granted to non-employee consultants are generally valued at the vesting date using an option pricing model that uses Level 3
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No nine September 30, 2020 2019.	Intangible and Long-Lived Assets We assess impairment of our long-lived assets using a "primary asset" approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not not No December 31, 2019 2018.
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not”	Income Taxes We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is “more likely than not”
New Accounting Pronouncements, Policy [Policy Text Block]	Significant New Accounting Pronouncements Recently Adopted Guidance In August 2018, ASU 2018 13, 820 December 15, 2019. January 1, 2020. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2020, ASU No. 2020 06, 470 20 815 40 December 15, 2023, may not We have reviewed other recent accounting pronouncements and concluded that they are either not no	Significant New Accounting Pronouncements Recently Adopted Guidance In February 2016, ASU, No. 2016 02, December 15, 2018 may January 1, 2019 not not $53,000 $75,700 In June 2018, ASU 2018 07, ASC 718, 1 2 3 December 15, 2018. January 1, 2019. not Unadopted Guidance In June 2016, ASU No. 2016 13, December 15, 2022, not In August 2018, ASU 2018 13, 820 December 15, 2019 not In August 2018, ASU 2018 15, December 15, 2019 not We have reviewed other recent accounting pronouncements and concluded that they are either not no
Lessee, Leases [Policy Text Block]	Leases We determine if an arrangement is or contains a lease at its inception. We have made accounting policy elections whereby we (i) do not 12 not ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. See Note 5,

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ – $ – $ 84,596 $ 84,596 Balance at December 31, 2019 $ – $ – $ 84,596 $ 84,596 Liability classified stock purchase warrants $ – $ – $ 44,954 $ 44,954 Balance at September 30, 2020 $ – $ – $ 44,954 $ 44,954	Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 84,596 $ 84,596 Balance at December 31, 2019 $ - $ - $ 84,596 $ 84,596
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Mark-to-market liabilities - Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 Balance at December 31, 2019 $ 84,596 Change in fair value - gain (39,642 ) Balance at September 30, 2020 $ 44,954	Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (499,138 ) Balance at December 31, 2019 $ 84,596 Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (3,269,148 ) Balance at December 31, 2018 $ 583,734

Note 4 - Stockholders' Equity (

Note 4 - Stockholders' Equity (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ – General and administrative expenses 180,571 294,600 Total $ 206,822 $ 294,600 Nine Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ 200,337 General and administrative expenses 497,710 561,007 Total $ 523,961 $ 761,344	Year Ended December 31, 2019 2018 Research and development costs $ 200,337 $ 133,334 General and administrative expenses 680,452 500,748 Total $ 880,789 $ 634,082
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2020 271,660 $ 61.83 7.8 $ – Granted 1,686,466 $ 0.62 Exercised – $ – $ – Forfeited (157,204 ) $ 15.53 Outstanding at September 30, 2020 1,800,922 $ 8.55 9.3 $ – Exercisable at September 30, 2020 710,884 $ 20.63 8.9 $ –	Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 $ - Exercised - - Forfeited/Expired (38,197 ) $ 67.90 Outstanding at December 31, 2019 271,660 $ 61.83 7.8 $ - Exercisable at December 31, 2019 207,813 $ 78.30 7.4 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number of Options Weighted-Average Weighted-Average Aggregate $0.62 1,686,466 $ 0.62 9.5 $ – $5.90 - $6.00 45,378 $ 5.99 8.8 – $7.20 - $8.80 6,380 $ 8.69 8.4 – $22.20 - $80.60 24,488 $ 31.15 4.8 – $107.40 - $1,102.40 38,210 $ 347.18 2.0 – 1,800,922 $ 8.55 9.3 $ –	Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 55,484 $ 5.99 9.5 $ - $7.20 - $8.80 146,972 $ 8.51 9.0 - $22.20 - $99.20 28,501 $ 31.63 5.7 - $107.40 - $1,102.41 40,703 $ 351.63 2.8 - 271,660 $ 61.83 7.8 $ -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2020 2019 Annual dividend - - Expected life (in years) 4.0 - 5.2 4.8 - 5.5 Risk free interest rate 0.2% - 0.3% 1.8% - 2.5% Expected volatility 110% - 111% 97% - 115%	Year Ended December 31, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.5% - 2.8% Expected volatility 97% - 115% 97% - 113%
Schedule of Share-based Compensation, Warrant Activity [Table Text Block]	Range of Exercise Prices Number of Range of Expiration Dates $0.90 - $1.25 3,233,407 May 2021 - May 2025 $1.70 - $3.38 1,493,999 December 2020 - January 2025 $6.00 - $782.60 199,337 October 2020 - April 2024 4,926,743	Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 24,650 March 2020 - July 2023 6,968,908
Restricted Stock [Member]
Notes Tables
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]		Shares of Restricted Stock Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 1,127 $ 22.20 Granted 15,689 $ 5.95 Vested (8,835 ) $ 8.03 Forfeited - $ - Outstanding at December 31, 2019 7,981 $ 5.95
Restricted Stock Units (RSUs) [Member]
Notes Tables
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]		Number of RSU's Weighted-Average Grant Date Fair Value Outstanding at January 1, 2019 2,816 $ 64.80 Granted 4,904 $ 5.90 Exercised and converted to common shares (1,127 ) $ 22.20 Forfeited (1,126 ) $ 22.20 Outstanding at December 31, 2019 5,467 $ 29.62 Exercisable at December 31, 2019 2,925 $ 50.23

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	2019 2018 Furniture and fixtures $ 35,407 $ 35,407 Computers and office equipment 138,897 138,897 Lab equipment 817,149 818,267 991,453 992,571 Less accumulated depreciation (950,417 ) (902,260 ) Property and equipment, net $ 41,036 $ 90,311

Note 6 - Patents (Tables)

Note 6 - Patents (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2019 2018 Patent asset $ 2,006,443 $ 2,006,443 Accumulated amortization (1,337,507 ) (1,242,900 ) Net intangibles $ 668,936 $ 763,543

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2019 2018 Current provision: Federal $ - $ - State - - Foreign - - Total current provision - - Deferred provision (benefit): Federal (545,792 ) 7,726 State 1,001,786 (2,749,386 ) Foreign - - Total deferred provision (benefit) 455,994 (2,741,660 ) Valuation allowance (455,994 ) 2,741,660 Consolidated income tax provision $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2019 2018 Federal statutory rate (21.0 %) (21.0 %) State income taxes, net of Federal benefits (5.3 %) (5.0 %) Rate changes (6.4 %) (66.3 %) Change in fair value of liability classified warrants (1.6 %) (17.3 %) Other, including non-deductible expenses 28.8 % 53.9 % Valuation allowance 5.5 % 55.7 % Total 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2019 2018 Net operating loss carryforwards $ 43,190,604 $ 42,580,533 Stock based compensation expense 2,605,277 2,643,471 Tax credit carryforwards and other 889,372 1,005,255 Gross deferred tax assets 46,685,253 46,229,259 Valuation allowance (46,685,253 ) (46,229,259 ) Net deferred tax assets $ - $ -

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	2020 2019 Operating lease cost $ 91,100 $ 141,300 Variable lease cost – 23,200 Sublease income – (86,100 ) Total net lease cost $ 91,100 $ 78,400	Operating lease cost $171,000 Variable lease cost 23,200 Sublease income (86,100) Total net lease cost $108,100
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future undiscounted cash flows: 2020 * $ 12,200 2021 55,900 2022 57,600 2023 59,400 2024 14,000 Total 199,100 Discount factor (39,700 ) Lease liability 159,400 Less current liability (37,100 ) Non-current lease liability $ 122,300	Future undiscounted cash flows: 2020 $ 53,503 2021 54,539 2022 56,190 2023 58,027 2024 13,650 Total 235,909 Discount factor (54,997 ) Lease liability 180,912 Less current liability (32,369 ) Non-current lease liability $ 148,543

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements 1 (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ – $ – $ 84,596 $ 84,596 Balance at December 31, 2019 $ – $ – $ 84,596 $ 84,596 Liability classified stock purchase warrants $ – $ – $ 44,954 $ 44,954 Balance at September 30, 2020 $ – $ – $ 44,954 $ 44,954	Level 1 Level 2 Level 3 Total Liabilities Liability classified stock purchase warrants $ - $ - $ 583,734 $ 583,734 Balance at December 31, 2018 $ - $ - $ 583,734 $ 583,734 Liability classified stock purchase warrants $ - $ - $ 84,596 $ 84,596 Balance at December 31, 2019 $ - $ - $ 84,596 $ 84,596
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Mark-to-market liabilities - Balance at December 31, 2018 $ 583,734 Change in fair value - gain (416,796 ) Balance at September 30, 2019 $ 166,938 Balance at December 31, 2019 $ 84,596 Change in fair value - gain (39,642 ) Balance at September 30, 2020 $ 44,954	Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2018 $ 583,734 Change in fair value - gain (499,138 ) Balance at December 31, 2019 $ 84,596 Mark-to-market liabilities - stock purchase warrants Balance at December 31, 2017 $ 3,852,882 Change in fair value - gain (3,269,148 ) Balance at December 31, 2018 $ 583,734

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity 1 (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ – General and administrative expenses 180,571 294,600 Total $ 206,822 $ 294,600 Nine Months Ended September 30, 2020 2019 Research and development expenses $ 26,251 $ 200,337 General and administrative expenses 497,710 561,007 Total $ 523,961 $ 761,344	Year Ended December 31, 2019 2018 Research and development costs $ 200,337 $ 133,334 General and administrative expenses 680,452 500,748 Total $ 880,789 $ 634,082
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted-Average Weighted-Average Aggregate Outstanding at January 1, 2020 271,660 $ 61.83 7.8 $ – Granted 1,686,466 $ 0.62 Exercised – $ – $ – Forfeited (157,204 ) $ 15.53 Outstanding at September 30, 2020 1,800,922 $ 8.55 9.3 $ – Exercisable at September 30, 2020 710,884 $ 20.63 8.9 $ –	Number of Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at January 1, 2019 81,674 $ 215.60 5.1 $ - Granted 228,183 $ 7.78 $ - Exercised - - Forfeited/Expired (38,197 ) $ 67.90 Outstanding at December 31, 2019 271,660 $ 61.83 7.8 $ - Exercisable at December 31, 2019 207,813 $ 78.30 7.4 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Range of Exercise Prices Number of Options Weighted-Average Weighted-Average Aggregate $0.62 1,686,466 $ 0.62 9.5 $ – $5.90 - $6.00 45,378 $ 5.99 8.8 – $7.20 - $8.80 6,380 $ 8.69 8.4 – $22.20 - $80.60 24,488 $ 31.15 4.8 – $107.40 - $1,102.40 38,210 $ 347.18 2.0 – 1,800,922 $ 8.55 9.3 $ –	Range of Exercise Prices Number of Options Outstanding Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value $5.90 - $6.00 55,484 $ 5.99 9.5 $ - $7.20 - $8.80 146,972 $ 8.51 9.0 - $22.20 - $99.20 28,501 $ 31.63 5.7 - $107.40 - $1,102.41 40,703 $ 351.63 2.8 - 271,660 $ 61.83 7.8 $ -
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Nine Months Ended September 30, 2020 2019 Annual dividend - - Expected life (in years) 4.0 - 5.2 4.8 - 5.5 Risk free interest rate 0.2% - 0.3% 1.8% - 2.5% Expected volatility 110% - 111% 97% - 115%	Year Ended December 31, 2019 2018 Annual dividend - - Expected life (in years) 4.8 - 5.5 2.5 - 5.3 Risk free interest rate 1.8% - 2.5% 2.5% - 2.8% Expected volatility 97% - 115% 97% - 113%
Schedule of Share-based Compensation, Warrant Activity [Table Text Block]	Range of Exercise Prices Number of Range of Expiration Dates $0.90 - $1.25 3,233,407 May 2021 - May 2025 $1.70 - $3.38 1,493,999 December 2020 - January 2025 $6.00 - $782.60 199,337 October 2020 - April 2024 4,926,743	Range of Exercise Prices Number of Warrants Outstanding Range of Expiration Dates $2.19 - $2.70 6,538,035 December 2020 - August 2024 $3.38 - $17.50 406,223 October 2023 - July 2024 $22.20 - $782.60 24,650 March 2020 - July 2023 6,968,908

Note 5 - Commitments and Cont_2

Note 5 - Commitments and Contingencies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	2020 2019 Operating lease cost $ 91,100 $ 141,300 Variable lease cost – 23,200 Sublease income – (86,100 ) Total net lease cost $ 91,100 $ 78,400	Operating lease cost $171,000 Variable lease cost 23,200 Sublease income (86,100) Total net lease cost $108,100
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Future undiscounted cash flows: 2020 * $ 12,200 2021 55,900 2022 57,600 2023 59,400 2024 14,000 Total 199,100 Discount factor (39,700 ) Lease liability 159,400 Less current liability (37,100 ) Non-current lease liability $ 122,300	Future undiscounted cash flows: 2020 $ 53,503 2021 54,539 2022 56,190 2023 58,027 2024 13,650 Total 235,909 Discount factor (54,997 ) Lease liability 180,912 Less current liability (32,369 ) Non-current lease liability $ 148,543

Note 7 - Disposal Group Asset_2

Note 7 - Disposal Group Assets Held for Sale (Tables)	9 Months Ended
	Sep. 30, 2020
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	September 30, 2020 Cash $ 100,367 Prepaid expesnes 143,836 Property and equipment, net 1,080 Patents, net 458,738 ROU and other assets 195,517 Disposal group assets held for sale $ 899,538 Accounts payable and accrued expenses $ 166,373 Lease liabilities 159,439 Disposal group liabilities associated with assets held for sale $ 325,812

Note 1 - Organization and Bus_2

Note 1 - Organization and Business and Financial Condition (Details Textual)	Jul. 17, 2019	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Number of Operating Segments			1	1
Stockholders' Equity Note, Stock Split, Conversion Ratio		20
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($) shares in Millions	6 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Cost Reimbursements from SBIR Grant as Offset to Research and Development Expenses		$ 58,900	$ 382,000	$ 459,000	$ 538,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		6.8	7.3	7.3	0.6
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0	$ 0
Operating Lease, Right-of-Use Asset	$ 204,300			$ 204,300
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset						$ 53,000
Operating Lease, Liability, Total						$ 75,700

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair value of liabilities	$ 44,954	$ 84,596	$ 583,734
Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	44,954	84,596	583,734
Fair Value, Inputs, Level 1 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 1 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 2 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 3 [Member]
Fair value of liabilities	44,954	84,596	583,734
Fair Value, Inputs, Level 3 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	$ 44,954	$ 84,596	$ 583,734

Note 3 - Fair Value Measureme_6

Note 3 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis (Details) - Stock Purchase Warrants [Member] - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 84,596	$ 583,734	$ 583,734	$ 3,852,882
Change in fair value - gain	(39,642)	(416,796)	(499,138)	(3,269,148)
Balance	$ 44,954	$ 166,938	$ 84,596	$ 583,734

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended							3 Months Ended	4 Months Ended	9 Months Ended		12 Months Ended
	May 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Feb. 28, 2019	Aug. 31, 2017	Dec. 31, 2016	May 31, 2016	Mar. 31, 2019	Jul. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)										7,100,000		7,441,532
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)										$ 0.52	$ 3.45	$ 3.45	$ 9.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value												$ 671,100	$ 205,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount												$ 155,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												219 days
Additional Research and Development Expense Due to Modifications								$ 102,000			$ 102,000
Proceeds from Warrant Exercises										$ 3,547,894	131	$ 236
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs												$ 6,552,842	1,828,000
Underwritten Public Offering [Member]
Number of Prefunded Units Sold (in shares)			2,361,462
Number of Units Sold (in shares)			416,315
Unit Price (in dollars per share)			$ 2.70						$ 2.70
Proceeds from Issuance or Sale of Equity, Total			$ 7,500,000
Number of Common Stock in Each Unit (in shares)			1						1
Number of Short-term Warrants in Each Unit (in shares)			1						1
Number of Long-term Warrants in Each Unit (in shares)			1						1
Number of Prefunded Warrants in Each Prefunded Unit (in shares)			1						1
Number of Short-term Warrants in Each Prefunded Unit (in shares)			1						1
Number of Long-term Warrants in Each Prefunded Unit (in shares)			1						1
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs			$ 6,600,000
Private Placement [Member]
Conversion of Stock, Shares Converted (in shares)			800,000						800,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)			155,496						155,496
Private Placement [Member] | Series A 4.5% Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)						200,000
Preferred Stock, Dividend Rate, Percentage						4.50%
Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)						38,873
Over-Allotment Option [Member]
Underwriters, Additional Common Shares Authorized to Purchase (in shares)			416,666
Underwriters, Additional Warrants Authorized to Purchase (in shares)			416,666
Stock Purchase Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	87,309			25,000	112,500		87,309
Class of Warrant or Right, Outstanding (in shares)										149,136		149,136
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.36		$ 6						$ 0.90		$ 2.70
Class of Warrant or Right, Granted During Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 3.80
Class of Warrant or Right, Vesting Percentage on Grant				25.00%
Class of Warrant or Right, Vesting Percentage on Completion of Initial Services				75.00%
Warrants and Rights Outstanding, Term (Year)				2 years 182 days
Proceeds from Warrant Exercises		$ 7,600,000
Class of Warrant or Right, Exercised During Period (in shares)		5,555,554
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.36
Stock Purchase Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.36
Proceeds from Warrant Exercises		$ 7,600,000
Class of Warrant or Right, Exercised During Period (in shares)		5,555,554
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.36
Stock Purchase Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0
Stock Purchase Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input				0.025
Stock Purchase Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input				1.1
Short-term Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.70						$ 2.70
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,194,443						3,194,443
Long-term warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 2.70						$ 2.70
Warrants and Rights Outstanding, Term (Year)			5 years						5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,194,443						3,194,443
Prefunded Warrants [Member]
Proceeds from Warrant Exercises												$ 200
Prefunded Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.0001						$ 0.0001
Equity Classified Warrants [Member] | Underwritten Public Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 3.375						$ 3.375
Warrants and Rights Outstanding, Term (Year)			5 years						5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			222,223						222,223
Replacement Stock Purchase Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		5,555,554
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.23
Replacement Stock Purchase Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Outstanding (in shares)		5,555,554
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.23
Stock Purchase Warrants With 2 Year Term [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		2 years
Stock Purchase Warrants With 2 Year Term [Member] | Subsequent Event [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		2 years
Stock Purchase Warrants With 5 Year Term [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		5 years
Stock Purchase Warrants With 5 Year Term [Member] | Subsequent Event [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		5 years
Placement Agent Stock Purchase Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	400,000	444,445
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.25	$ 1.70
Warrants and Rights Outstanding, Term (Year)	5 years	5 years
Placement Agent Stock Purchase Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Outstanding (in shares)		444,445
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.70
Warrants and Rights Outstanding, Term (Year)		5 years
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount										$ 8,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										182 days		182 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding										$ 16,800		$ 5,400
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value										23,400	6,400	13,900	$ 50,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested										$ 300	$ 10,400	$ 10,400
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in shares)										563	1,126	1,127	0
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount												$ 15,000
Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												182 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding										$ 2,600	$ 14,500	$ 7,900
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested												18,500
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in shares)										0	15,688
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount												$ 47,500

Note 4 - Stockholders' Equity -

Note 4 - Stockholders' Equity - Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Share-based compensation expense	$ 206,822	$ 294,600	$ 523,961	$ 761,344	$ 880,789	$ 634,082
Research and Development Expense [Member]
Share-based compensation expense	26,251		26,251	200,337	200,337	133,334
General and Administrative Expense [Member]
Share-based compensation expense	$ 180,571	$ 294,600	$ 497,710	$ 561,007	$ 680,452	$ 500,748

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity - Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Options Outstanding (in shares)	271,660	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 61.83	$ 215.60
Weighted- average remaining contractual life (Year)	9 years 109 days	7 years 292 days	5 years 36 days
Options Granted (in shares)	1,686,466	228,183
Options Granted, Weighted Average Exercise Price (in dollars per share)	$ 0.62	$ 7.78
Options Exercised (in shares)
Options Exercised, Weighted Average Exercise Price (in dollars per share)
Options Forfeited/Expired (in shares)	(157,204)	(38,197)
Options Forfeited/Expired, Weighted Average Exercise Price (in dollars per share)	$ 15.53	$ 67.90
Options Outstanding (in shares)	1,800,922	271,660	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 8.55	$ 61.83	$ 215.60
Options Exercisable (in shares)	710,884	207,813
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 20.63	$ 78.30
Options Exercisable, Weighted Average Remaining Contractual Life (Year)	8 years 328 days	7 years 146 days

Note 4 - Stockholders' Equity_5

Note 4 - Stockholders' Equity - Stock Options by Exercise Price Range (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of options outstanding (in shares)	1,800,922	271,660
Weighted- average exercise price (in dollars per share)	$ 8.55	$ 61.83	$ 215.60
Weighted- average remaining contractual life (Year)	9 years 109 days	7 years 292 days	5 years 36 days
Aggregate intrinsic value
Range One [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 0.62	$ 5.90
Range of exercise prices, upper limit (in dollars per share)	$ 0.62	$ 6
Number of options outstanding (in shares)	1,686,466	55,484
Weighted- average exercise price (in dollars per share)	$ 0.62	$ 5.99
Weighted- average remaining contractual life (Year)	9 years 182 days	9 years 182 days
Aggregate intrinsic value
Range Two [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 5.90	$ 7.20
Range of exercise prices, upper limit (in dollars per share)	$ 6	$ 8.80
Number of options outstanding (in shares)	45,378	146,972
Weighted- average exercise price (in dollars per share)	$ 5.99	$ 8.51
Weighted- average remaining contractual life (Year)	8 years 292 days	9 years
Aggregate intrinsic value
Range Three [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 7.20	$ 22.20
Range of exercise prices, upper limit (in dollars per share)	$ 8.80	$ 99.20
Number of options outstanding (in shares)	6,380	28,501
Weighted- average exercise price (in dollars per share)	$ 8.69	$ 31.63
Weighted- average remaining contractual life (Year)	8 years 146 days	5 years 255 days
Aggregate intrinsic value
Range Four [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 22.20	$ 107.40
Range of exercise prices, upper limit (in dollars per share)	$ 80.60	$ 1,102.41
Number of options outstanding (in shares)	24,488	40,703
Weighted- average exercise price (in dollars per share)	$ 31.15	$ 351.63
Weighted- average remaining contractual life (Year)	4 years 292 days	2 years 292 days
Aggregate intrinsic value

Note 4 - Stockholders' Equity_6

Note 4 - Stockholders' Equity - Fair Value Assumptions for Stock Options (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Annual dividend
Minimum [Member]
Annual dividend
Expected life (Year)	4 years	4 years 292 days	4 years 292 days	2 years 182 days
Risk free interest rate	0.20%	1.80%	1.80%	2.50%
Expected volatility	110.00%	97.00%	97.00%	97.00%
Maximum [Member]
Annual dividend
Expected life (Year)	5 years 73 days	5 years 182 days	5 years 182 days	5 years 109 days
Risk free interest rate	0.30%	2.50%	2.50%	2.80%
Expected volatility	111.00%	115.00%	115.00%	113.00%

Note 4 - Stockholders' Equity_7

Note 4 - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Outstanding (in shares)	5,467	2,816	2,816
Outstanding, Weighted Average Grant Date Fair Value (in dollars per share)	$ 29.62	$ 64.80	$ 64.80
Granted (in shares)			4,904
Granted, Weighted Average Grant Date Fair Value (in dollars per share)			$ 5.90
Exercised and converted to common shares (in shares)	(563)	(1,126)	(1,127)	0
Exercised and converted to common shares, Weighted Average Grant Date Fair Value (in dollars per share)			$ 22.20
Forfeited (in shares)			(1,126)
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)			$ 22.20
Outstanding (in shares)			5,467	2,816
Outstanding, Weighted Average Grant Date Fair Value (in dollars per share)			$ 29.62	$ 64.80
Exercisable (in shares)			2,925
Exercisable, Weighted Average Grant Date Fair Value (in dollars per share)			$ 50.23

Note 4 - Stockholders' Equity_8

Note 4 - Stockholders' Equity - Summary of Restricted Stock Activity (Details) - Restricted Stock [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2019
Outstanding (in shares)	1,127	1,127
Outstanding at January 1, 2019 (in dollars per share)	$ 22.20	$ 22.20
Granted (in shares)		15,689
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	$ 5.95	$ 5.95
Vested (in shares)		(8,835)
Vested, Weighted Average Grant Date Fair Value (in dollars per share)		$ 8.03
Outstanding (in shares)		7,981
Outstanding at December 31, 2019 (in dollars per share)		$ 5.95

Note 4 - Stockholders' Equity_9

Note 4 - Stockholders' Equity - Summary of Warrant Activity (Details) - Stock Purchase Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Number of warrants outstanding (in shares)	4,926,743
Range Two [Member]
Lower exercise price range (in dollars per share)	$ 1.70	$ 2.19
Upper range of exercise prices (in dollars per share)	$ 3.38	$ 2.70
Number of warrants outstanding (in shares)	1,493,999	6,538,035
Range Two [Member] | Minimum [Member]
Expiration dates	December 2020	December 2020
Range Two [Member] | Maximum [Member]
Expiration dates	January 2025	August 2024
Range Three [Member]
Lower exercise price range (in dollars per share)	$ 6	$ 3.38
Upper range of exercise prices (in dollars per share)	$ 782.60	$ 17.50
Number of warrants outstanding (in shares)	199,337	406,223
Range Three [Member] | Minimum [Member]
Expiration dates	October 2020	October 2023
Range Three [Member] | Maximum [Member]
Expiration dates	April 2024	July 2024
Range Four [Member]
Lower exercise price range (in dollars per share)		$ 22.20
Upper range of exercise prices (in dollars per share)		$ 782.60
Number of warrants outstanding (in shares)		24,650
Range Four [Member] | Minimum [Member]
Expiration dates		March 2020
Range Four [Member] | Maximum [Member]
Expiration dates		July 2023
Range One [Member]
Lower exercise price range (in dollars per share)	$ 0.90
Upper range of exercise prices (in dollars per share)	$ 1.25	$ 0.0001
Number of warrants outstanding (in shares)	3,233,407	6,968,908
Range One [Member] | Minimum [Member]
Expiration dates	May 2021
Range One [Member] | Maximum [Member]
Expiration dates	May 2025

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment, Gross, Ending Balance	$ 991,453	$ 992,571
Depreciation, Total	49,000	$ 84,000
CHINA
Property, Plant and Equipment, Gross, Ending Balance	$ 70,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Major Classes of Property and Equipment (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Property and equipment, gross		$ 991,453	$ 992,571
Less accumulated depreciation		(950,417)	(902,260)
Property and equipment, net	$ 15,040	41,036	90,311
Furniture and Fixtures [Member]
Property and equipment, gross		35,407	35,407
Office Equipment [Member]
Property and equipment, gross		138,897	138,897
Equipment [Member]
Property and equipment, gross		$ 817,149	$ 818,267

Note 6 - Patents (Details Textu

Note 6 - Patents (Details Textual) - USD ($)	6 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0	$ 0
Amortization of Intangible Assets, Total				95,000	$ 102,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 75,000			$ 75,000

Note 6 - Patents - Intangible A

Note 6 - Patents - Intangible Assets and Accumulated Amortization (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Patent asset	$ 2,006,443	$ 2,006,443
Accumulated amortization	(1,337,507)	(1,242,900)
Net intangibles	$ 668,936	$ 763,543

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Millions	Dec. 31, 2019	Dec. 31, 2017
Operating Loss Carryforwards, Total	$ 160
Tax Year 2019 [Member]
Operating Loss Carryforwards, Subject to Expiration		$ 146

Note 7 - Income Taxes - Provisi

Note 7 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Federal
State
Foreign
Total current provision
Federal	(545,792)	7,726
State	1,001,786	(2,749,386)
Foreign		0
Total deferred provision (benefit)	455,994	(2,741,660)
Valuation allowance	(455,994)	2,741,660
Consolidated income tax provision

Note 7 - Income Taxes - Effecti

Note 7 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Federal statutory rate	(21.00%)	(21.00%)
State income taxes, net of Federal benefits	(5.30%)	(5.00%)
Rate changes	(6.40%)	(66.30%)
Change in fair value of liability classified warrants	(1.60%)	(17.30%)
Other, including non-deductible expenses	28.80%	53.90%
Valuation allowance	5.50%	55.70%
Total	0.00%	0.00%

Note 7 - Income Taxes - Tax Eff

Note 7 - Income Taxes - Tax Effects of Significant Temporary Differences Representing Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Net operating loss carryforwards	$ 43,190,604	$ 42,580,533
Stock based compensation expense	2,605,277	2,643,471
Tax credit carryforwards and other	889,372	1,005,255
Gross deferred tax assets	46,685,253	46,229,259
Valuation allowance	(46,685,253)	(46,229,259)
Net deferred tax assets

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual)	1 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)ft²	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)ft²	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)
Sublease Income			$ 86,100	$ 86,100
Operating Lease, Expense		91,100	164,500	194,200	$ 164,000
Operating Lease, Right-of-Use Asset				$ 204,300
Lessee, Operating Lease, Discount Rate				12.75%
Other Assets [Member]
Operating Lease, Right-of-Use Asset		181,800		$ 201,700
Other Current Assets and Lease Liability, Net of Current Portion [Member]
Operating Lease, Liability, Total				180,900
Short-term Leases [Member]
Operating Lease, Expense		$ 50,700	$ 83,900	$ 67,700
UNITED STATES
Number of Facilities		1		1
CHINA
Number of Facilities		1		1
Area of Real Estate Property (Square Foot) | ft²	11,300		11,300
Lease Monthly Payment	$ 4,400
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 205,000
Germantown, MD [Member]
Area of Real Estate Property (Square Foot) | ft²		1,500		1,500
Lease Monthly Payment		$ 5,600		$ 5,700
Lessee, Operating Lease, Term of Contract (Month)				1 year	1 year

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Lease Cost (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Operating lease cost	$ 91,100	$ 141,300	$ 171,000
Variable lease cost		23,200	23,200
Sublease income		(86,100)	(86,100)
Total net lease cost	$ 91,100	$ 78,400	$ 108,100

Note 8 - Commitments and Cont_5

Note 8 - Commitments and Contingencies - Maturities of Operating Lease (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
2020	$ 55,900	$ 53,503
2021	57,600	54,539
2022	59,400	56,190
2023	14,000	58,027
2024		13,650
Total	199,100	235,909
Discount factor	(39,700)	(54,997)
Non-current lease liability		148,543
Liabilities [Member]
Lease liability	159,400	180,912
Current Liabilities [Member]
Less current liability	$ (37,100)	$ (32,369)

Note 9 - Related Party Receiv_2

Note 9 - Related Party Receivable (Details Textual) - Chief Scientific Officer [Member] - Repayment Agreement of Improperly Expense Reimbursement [Member] - USD ($)	Aug. 10, 2016	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Due from Related Parties, Term (Year)	6 years
Due from Related Parties, Total	$ 658,000		$ 229,000	$ 229,000
Due from Related Party, Discount	$ 199,000
Debt Instrument, Decrease, Forgiveness		$ 229,000

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	Mar. 23, 2020	Jan. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Proceeds from Warrant Exercises			$ 3,547,894	$ 131	$ 236
Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)		5,555,554
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.36
Proceeds from Warrant Exercises		$ 7,600,000
Subsequent Event [Member] | Inducement Award Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	715,000
Subsequent Event [Member] | Stock Purchase Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)		5,555,554
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.36
Proceeds from Warrant Exercises		$ 7,600,000

Note 1 - Organization, Busine_2

Note 1 - Organization, Business and Financial Condition (Details Textual)	Jul. 17, 2019	Sep. 30, 2019	Sep. 30, 2020	Dec. 31, 2019
Number of Operating Segments			1	1
Stockholders' Equity Note, Stock Split, Conversion Ratio		20
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	20

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies and Basis of Presentation (Details Textual) - USD ($) shares in Millions	6 Months Ended	9 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 5,114,917	$ 12,651,728		$ 5,114,917	$ 5,787,110
Cost Reimbursements from SBIR Grant as Offset to Research and Development Expenses		$ 58,900	$ 382,000	$ 459,000	$ 538,000
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		6.8	7.3	7.3	0.6
Asset Impairment Charges, Total	$ 0	$ 0	$ 0	$ 0	$ 0
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents		$ 100,367

Note 3 - Fair Value Measureme_7

Note 3 - Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis 1 (Details) - Fair Value, Recurring [Member] - USD ($)	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Fair value of liabilities	$ 44,954	$ 84,596	$ 583,734
Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	44,954	84,596	583,734
Fair Value, Inputs, Level 1 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 1 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 2 [Member]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants
Fair Value, Inputs, Level 3 [Member]
Fair value of liabilities	44,954	84,596	583,734
Fair Value, Inputs, Level 3 [Member] | Stock Purchase Warrants [Member]
Liability classified stock purchase warrants	$ 44,954	$ 84,596	$ 583,734

Note 3 - Fair Value Measureme_8

Note 3 - Fair Value Measurements - Activity for Items Measured at Fair Value on a Recurring Basis 1 (Details) - Stock Purchase Warrants [Member] - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Balance	$ 84,596	$ 583,734	$ 583,734	$ 3,852,882
Change in fair value - gain	(39,642)	(416,796)	(499,138)	(3,269,148)
Balance	$ 44,954	$ 166,938	$ 84,596	$ 583,734

Note 4 - Stockholders' Equit_10

Note 4 - Stockholders' Equity 1 (Details Textual) - USD ($)	1 Months Ended							3 Months Ended			4 Months Ended	9 Months Ended		12 Months Ended
	May 31, 2020	Jan. 31, 2020	Jul. 31, 2019	Feb. 28, 2019	Aug. 31, 2017	Dec. 31, 2016	May 31, 2016	Sep. 30, 2020	Sep. 30, 2019	Mar. 31, 2019	Jul. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)												10 years		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								7,100,000				7,100,000		7,441,532
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)												$ 0.52	$ 3.45	$ 3.45	$ 9.40
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount														$ 155,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)														219 days
Additional Research and Development Expense Due to Modifications										$ 102,000			$ 102,000
Proceeds from Warrant Exercises												$ 3,547,894	131	$ 236
Warrant Inducement Expense												5,620,089
Proceeds from Issuance of Common Stock, Net												$ 11,150,318	$ 6,552,842
Private Placement [Member]
Conversion of Stock, Shares Converted (in shares)			800,000								800,000
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)			155,496								155,496
May 2020 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	5,000,000
Shares Issued, Price Per Share (in dollars per share)	$ 1
Proceeds from Issuance of Common Stock	$ 5,000,000
Proceeds from Issuance of Common Stock, Net	$ 4,400,000
Series A 4.5% Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Shares, New Issues (in shares)						200,000
Preferred Stock, Dividend Rate, Percentage						4.50%
Convertible Preferred Stock, Issuable Upon Conversion of All Shares (in shares)						38,873
Stock Purchase Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	87,309			25,000	112,500		87,309
Class of Warrant or Right, Outstanding (in shares)								149,136				149,136		149,136
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.36		$ 6				$ 0.90				$ 0.90		$ 2.70
Class of Warrant or Right, Exercised During Period (in shares)		5,555,554
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)		$ 1.36
Proceeds from Warrant Exercises		$ 7,600,000
Warrants and Rights Outstanding, Term (Year)				2 years 182 days
Warrant Inducement Expense												$ 5,600,000
Replacement Stock Purchase Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		5,555,554
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.23
Stock Purchase Warrants With 2 Year Term [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		2 years
Stock Purchase Warrants With 5 Year Term [Member]
Class of Warrant or Right, Outstanding (in shares)		2,777,777
Warrants and Rights Outstanding, Term (Year)		5 years
Placement Agent Stock Purchase Warrants [Member]
Class of Warrant or Right, Issued During Period (in shares)	400,000	444,445
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.25	$ 1.70
Warrants and Rights Outstanding, Term (Year)	5 years	5 years
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 587,000				$ 587,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												2 years 182 days
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount								$ 8,000				$ 8,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)												182 days		182 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted (in shares)												24,000	4,904
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value												$ 23,400	$ 6,400	$ 13,900	$ 50,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)								28,904				28,904
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value (in dollars per share)								$ 1.58				$ 1.58
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding								$ 16,800				$ 16,800		$ 5,400
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in shares)												563	1,126	1,127	0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested												$ 300	$ 10,400	$ 10,400
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)														$ 5.90
Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)														182 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value (in dollars per share)								$ 5.90	$ 9.73			$ 5.90	$ 9.73
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding								$ 2,600	$ 14,500			$ 2,600	$ 14,500	$ 7,900
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised (in shares)												0	15,688
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested														$ 18,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)													$ 5.95	$ 5.95
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)								0				0		7,981	1,127

Note 4 - Stockholders' Equit_11

Note 4 - Stockholders' Equity - Share-based Compensation Expense 1 (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Share-based compensation expense	$ 206,822	$ 294,600	$ 523,961	$ 761,344	$ 880,789	$ 634,082
Research and Development Expense [Member]
Share-based compensation expense	26,251		26,251	200,337	200,337	133,334
General and Administrative Expense [Member]
Share-based compensation expense	$ 180,571	$ 294,600	$ 497,710	$ 561,007	$ 680,452	$ 500,748

Note 4 - Stockholders' Equit_12

Note 4 - Stockholders' Equity - Summary of Stock Option Activity 1 (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Options Outstanding (in shares)	271,660	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 61.83	$ 215.60
Weighted- average remaining contractual life (Year)	9 years 109 days	7 years 292 days	5 years 36 days
Options Granted (in shares)	1,686,466	228,183
Options Granted, Weighted Average Exercise Price (in dollars per share)	$ 0.62	$ 7.78
Options Exercised (in shares)
Options Exercised, Weighted Average Exercise Price (in dollars per share)
Options Forfeited/Expired (in shares)	(157,204)	(38,197)
Options Forfeited/Expired, Weighted Average Exercise Price (in dollars per share)	$ 15.53	$ 67.90
Options Outstanding (in shares)	1,800,922	271,660	81,674
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 8.55	$ 61.83	$ 215.60
Options Exercisable (in shares)	710,884	207,813
Options Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 20.63	$ 78.30
Options Exercisable, Weighted Average Remaining Contractual Life (Year)	8 years 328 days	7 years 146 days

Note 4 - Stockholders' Equit_13

Note 4 - Stockholders' Equity - Stock Options by Exercise Price Range 1 (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Number of options outstanding (in shares)	1,800,922	271,660
Weighted- average exercise price (in dollars per share)	$ 8.55	$ 61.83	$ 215.60
Weighted- average remaining contractual life (Year)	9 years 109 days	7 years 292 days	5 years 36 days
Range One [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 0.62	$ 5.90
Range of exercise prices, upper limit (in dollars per share)	$ 0.62	$ 6
Number of options outstanding (in shares)	1,686,466	55,484
Weighted- average exercise price (in dollars per share)	$ 0.62	$ 5.99
Weighted- average remaining contractual life (Year)	9 years 182 days	9 years 182 days
Range Two [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 5.90	$ 7.20
Range of exercise prices, upper limit (in dollars per share)	$ 6	$ 8.80
Number of options outstanding (in shares)	45,378	146,972
Weighted- average exercise price (in dollars per share)	$ 5.99	$ 8.51
Weighted- average remaining contractual life (Year)	8 years 292 days	9 years
Range Three [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 7.20	$ 22.20
Range of exercise prices, upper limit (in dollars per share)	$ 8.80	$ 99.20
Number of options outstanding (in shares)	6,380	28,501
Weighted- average exercise price (in dollars per share)	$ 8.69	$ 31.63
Weighted- average remaining contractual life (Year)	8 years 146 days	5 years 255 days
Range Four [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 22.20	$ 107.40
Range of exercise prices, upper limit (in dollars per share)	$ 80.60	$ 1,102.41
Number of options outstanding (in shares)	24,488	40,703
Weighted- average exercise price (in dollars per share)	$ 31.15	$ 351.63
Weighted- average remaining contractual life (Year)	4 years 292 days	2 years 292 days
Range Five [Member]
Range of exercise prices, lower limit (in dollars per share)	$ 107.40
Range of exercise prices, upper limit (in dollars per share)	$ 1,102.40
Number of options outstanding (in shares)	38,210
Weighted- average exercise price (in dollars per share)	$ 347.18
Weighted- average remaining contractual life (Year)	2 years

Note 4 - Stockholders' Equit_14

Note 4 - Stockholders' Equity - Fair Value Assumptions for Stock Options 1 (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Annual dividend
Minimum [Member]
Annual dividend
Expected life (Year)	4 years	4 years 292 days	4 years 292 days	2 years 182 days
Risk free interest rate	0.20%	1.80%	1.80%	2.50%
Expected volatility	110.00%	97.00%	97.00%	97.00%
Maximum [Member]
Annual dividend
Expected life (Year)	5 years 73 days	5 years 182 days	5 years 182 days	5 years 109 days
Risk free interest rate	0.30%	2.50%	2.50%	2.80%
Expected volatility	111.00%	115.00%	115.00%	113.00%

Note 4 - Stockholders' Equit_15

Note 4 - Stockholders' Equity - Summary of Warrant Activity 1 (Details) - Stock Purchase Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Number of warrants outstanding (in shares)	4,926,743
Range One [Member]
Lower exercise price range (in dollars per share)	$ 0.90
Upper range of exercise prices (in dollars per share)	$ 1.25	$ 0.0001
Number of warrants outstanding (in shares)	3,233,407	6,968,908
Range One [Member] | Minimum [Member]
Expiration dates	May 2021
Range One [Member] | Maximum [Member]
Expiration dates	May 2025
Range Two [Member]
Lower exercise price range (in dollars per share)	$ 1.70	$ 2.19
Upper range of exercise prices (in dollars per share)	$ 3.38	$ 2.70
Number of warrants outstanding (in shares)	1,493,999	6,538,035
Range Two [Member] | Minimum [Member]
Expiration dates	December 2020	December 2020
Range Two [Member] | Maximum [Member]
Expiration dates	January 2025	August 2024
Range Three [Member]
Lower exercise price range (in dollars per share)	$ 6	$ 3.38
Upper range of exercise prices (in dollars per share)	$ 782.60	$ 17.50
Number of warrants outstanding (in shares)	199,337	406,223
Range Three [Member] | Minimum [Member]
Expiration dates	October 2020	October 2023
Range Three [Member] | Maximum [Member]
Expiration dates	April 2024	July 2024

Note 5 - Commitments and Cont_3

Note 5 - Commitments and Contingencies (Details Textual)	1 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)ft²	Sep. 30, 2020USD ($)ft²	Sep. 30, 2019USD ($)ft²	Dec. 31, 2019USD ($)ft²	Dec. 31, 2018USD ($)
Sublease Income			$ 86,100	$ 86,100
Operating Lease, Expense		91,100	164,500	194,200	$ 164,000
Operating Lease, Right-of-Use Asset				204,300
Other Assets [Member]
Operating Lease, Right-of-Use Asset		181,800		201,700
Short-term Notes and Other Current Liabilities and Lease Liability, Net of Current Portion [Member]
Operating Lease, Liability, Total		159,400
Short-term Leases [Member]
Operating Lease, Expense		$ 50,700	$ 83,900	$ 67,700
UNITED STATES
Number of Facilities		1		1
CHINA
Number of Facilities		1		1
Area of Real Estate Property (Square Foot) | ft²	11,300		11,300
Lease Monthly Payment	$ 4,400
Germantown, MD [Member]
Area of Real Estate Property (Square Foot) | ft²		1,500		1,500
Lease Monthly Payment		$ 5,600		$ 5,700
Lessee, Operating Lease, Term of Contract (Month)				1 year	1 year

Note 5 - Commitments and Cont_4

Note 5 - Commitments and Contingencies - Lease Cost (Details) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Operating lease cost	$ 91,100	$ 141,300	$ 171,000
Variable lease cost		23,200	23,200
Sublease income		(86,100)	(86,100)
Total net lease cost	$ 91,100	$ 78,400	$ 108,100

Note 5 - Commitments and Cont_5

Note 5 - Commitments and Contingencies - Maturities of Operating Lease (Details) - USD ($)		Sep. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
2020	[1]	$ 12,200
2020		55,900	$ 53,503
2021		57,600	54,539
2022		59,400	56,190
2023		14,000	58,027
Total		199,100	235,909
Discount factor		(39,700)	(54,997)
Non-current lease liability			148,543
Liabilities [Member]
Lease liability		159,400	180,912
Current Liabilities [Member]
Less current liability		(37,100)	$ (32,369)
Disposal Group Assets [Member]
Non-current lease liability		$ 122,300
[1]	reflects the remaining 3 months of 2020

Note 6 - Related Party Receiv_2

Note 6 - Related Party Receivable (Details Textual) - Chief Scientific Officer [Member] - Repayment Agreement of Improperly Expense Reimbursement [Member] - USD ($)	Aug. 10, 2016	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Due from Related Parties, Term (Year)	6 years
Due from Related Parties, Total	$ 658,000		$ 229,000	$ 229,000
Due from Related Party, Discount	$ 199,000
Debt Instrument, Decrease, Forgiveness		$ 229,000

Note 7 - Disposal Group Asset_3

Note 7 - Disposal Group Assets Held for Sale - Disposal Group Held for Sale Assets and Liabilities (Details) - USD ($)	Sep. 30, 2020	Dec. 31, 2019
Disposal group assets held for sale	$ 899,538
Disposal group liabilities associated with assets held for sale	325,812
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	100,367
Prepaid expesnes	143,836
Property and equipment, net	1,080
Patents, net	458,738
ROU and other assets	195,517
Disposal group assets held for sale	899,538
Accounts payable and accrued expenses	166,373
Lease liabilities	159,439
Disposal group liabilities associated with assets held for sale	$ 325,812